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Chapter 1: Introduction 
 
Proopiomelanocortin (POMC) is a pre-propeptide encoded by the Pomc gene, which is 
expressed predominantly in the hypothalamus and pituitary (1-3). The POMC propeptide is 
subsequently cleaved by processing enzymes in a tissue-specific manner, yielding multiple 
bioactive peptides (Figure 1.1). In anterior pituitary corticotrophs, POMC is processed into 
adrenocorticotropic hormone (ACTH) and released into the bloodstream where it regulates 
glucocorticoid (GC) production and release from the adrenal glands (2,3). Peripheral ACTH is 
also critical for proper adrenal gland development and is a major signaling molecule in the 
hypothalamic-pituitary-adrenal (HPA) stress axis (4). In the hypothalamus, Pomc is expressed in 
a small group of ~3,000 neurons in the arcuate nucleus (Arc) (5). There, the POMC propeptide is 
processed into ACTH, as well as α- and γ-melanocyte stimulating hormone (MSH), and the 
opioid β-endorphin (2,3). Together, ACTH and α- and γ-MSH are referred to as the 
melanocortins, as these peptides activate downstream melanocortin receptors. There are five 
known melanocortin receptors, Mc1r-Mc5r, which are all G-protein coupled receptors. Mc1r is 
expressed in the skin and is involved in pigmentation, and Mc5r is expressed in exocrine glands. 
Mc2r, also known as the ACTH receptor, is expressed in the adrenal cortex where it is necessary 
for ACTH signaling in the HPA axis. Mc3r and Mc4r are primarily expressed in the central 
nervous system (CNS) (6,7).  
The Pomc, Mc3r, and Mc4r genes are conserved in all major groups of jawed vertebrates, 
and POMC-expressing neuronal cell bodies are restricted to the hypothalamus and brain stem in  
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cartilaginous and bony fishes as well as tetrapods including mammals (8,9). Such strong 
evolutionary conservation highlights the important physiological role of POMC. Due to their 
proximity to the median eminence, POMC neurons are uniquely situated to receive peripheral 
signals via blood-borne molecules (10,11). Indeed, the discovery that direct injection of 
melanocortins into the brain inhibited both spontaneous and drug-induced feeding in rats (12) 
suggested that POMC neurons may sense and respond to signals of nutritional status. In the past 
30 years, a great deal of research has focused on unraveling how melanocortins control both food 
intake and energy expenditure. Immense progress has been made in this field, and has been 
extensively reviewed elsewhere (6,13-16). Some of these studies have revealed that POMC plays 
a critical role in physiological processes other than energy balance, including the cardiovascular 
and immune systems (17,18). Here, I will briefly describe the classical working model of the 
melanocortin system as well as highlight some of the exciting tools, techniques and ideas that 
have been generated recently to study the physiological role of POMC in the brain (Section I). I 
will then provide a detailed discussion of two slightly less well-studied roles of CNS 
melanocortins: Regulation of locomotor activity (Section II) and interaction with the HPA stress 
axis (Section III).  
 
I. The neural melanocortin system 
 
A. Classical model 
 
In addition to POMC, an endogenous melanocortin receptor competitive antagonist, 
agouti-related peptide (AGRP), is produced in a separate small group of adjacent neurons in the 
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Arc (19,20). Collectively, POMC and AGRP neurons, their projecting fibers, target neurons 
expressing Mc3r or Mc4r, and a second small group of Pomc-expressing neurons in the brain 
stem, define the neural melanocortin system (21,22) (Figure 1.2). Through a combination of 
studies using pharmacological manipulation, genetic knockout mouse models, and 
electrophysiological recordings, an early model of how the melanocortin system regulates energy 
homeostasis was formed.  
The early “yin/yang” model suggested that feeding and energy expenditure are directly 
controlled via two peptides, α-MSH and AGRP, acting on melanocortin receptors throughout the 
brain. POMC and AGRP neurons send projections to cells expressing either Mc3r, important for 
energy partitioning, or Mc4r, controlling food intake and energy expenditure. α-MSH-induced 
activation of melanocortin receptors decreases food intake and increases energy expenditure, and 
AGRP antagonizes these effects. Pomc-KO and Mc4r-KO mice are morbidly obese and 
hyperphagic, whereas Mc3r-KO mice have increased fat mass, and Agrp-KO mice have no 
metabolic phenotype (23-29). 
Circulating nutrients and hormones can both directly and indirectly modulate these 
neurons. Early studies focused on leptin, an adipocyte-derived hormone. Circulating leptin levels 
are a direct proxy for an animal’s energy stores, and leptin activates POMC neurons and 
increases Pomc mRNA levels while inhibiting AGRP neurons and decreasing Agrp mRNA 
levels directly via the long form of the leptin receptor (LepRb), which is expressed on both cell 
types (5,30-35). Leptin signaling also depolarizes POMC neurons via activation of TRPC 
channels (36). Furthermore, leptin depolarizes POMC neurons through reduction of an inhibitory 
tone from AGRP neurons conveyed by both neuropeptide Y (NPY) and γ-aminobutyric acid 
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(GABA) (5). In addition to leptin, POMC and AGRP neurons are now known to also respond to 
insulin, estrogen, ghrelin, glucose and fatty acids in an opposing manner (37-46).  
Conditional genetic knockouts have been generated to further parse how the two 
networks of melanocortin neurons drive energy homeostasis. Pomc-Cre and Agrp-Cre mice were 
generated and crossed with strains engineered to contain floxed alleles of other genes of interest, 
resulting in specific deletion or re-expression of that gene in only POMC or AGRP neurons 
(47,48). These studies have begun to identify how specific hormones directly affect each cell 
population and, for example, suggested a direct role for POMC neurons in the anorectic response 
to leptin, estrogen, and serotonin (47,49,50). However, these results should be interpreted with 
caution as it was also recently discovered that Pomc is expressed transiently during development 
in neurons that later go on to become AGRP or kisspeptin neurons, and thus Pomc-Cre may be 
active during development in these cells (51-53).  
 
B. Recent discoveries 
 
The dual peptide model of melanocortin action has held up well, and recent technological 
advances have yielded further exciting findings [for review, see (54-56)]. In vivo calcium 
imaging has shown that POMC and AGRP neurons respond rapidly to sensory food cues even 
before ingestion, and that the response varies with nutritional state and depends on the 
palatability of the food presented (57,58). Thus, in addition to long-term integration of nutritional 
signals and control of homeostasis, the melanocortin system appears to be dynamically regulated 
by sensory stimuli and may be directly involved in food-seeking behavior. 
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POMC and AGRP neurons usually, but not always, project to the same nuclei, suggesting 
a possible role for each peptide independently of the other (59,60). For years there has been 
disagreement in the field as to whether Mc4r is constitutively active and therefore if AGRP acts 
as a competitive antagonist or an inverse agonist at this receptor (61). The signaling cascade 
downstream of Mc4r activation has now been more extensively studied. Recent experiments 
suggest that not only can Mc4r couple to multiple G-proteins and therefore signal via a wide 
variety of downstream signaling cascades, it can also act independently of G-proteins to 
modulate the gating of potassium channels. Furthermore, AGRP can selectively activate specific 
pathways and act as a biased agonist (62,63). 
Agrp-KO mice have no metabolic phenotype, as mentioned above, but postnatal ablation 
of AGRP neurons resulted in rapid starvation (29,64,65), which initially suggested 
developmental compensation in the knockout model. Surprisingly, though, an additional and 
clever series of neuronal ablation studies identified that the starvation was independent of 
melanocortin signaling and was mediated in part by the fast neurotransmitter GABA (66-68). 
Further, opto-and chemo-genetic activation of AGRP neurons led to immediate and voracious 
hyperphagia, also independent of melanocortin signaling (69-71). Additional genetic and 
pharmacological experiments revealed that GABA and NPY released by AGRP neurons each 
play a critical role in this immediate feeding behavior, whereas AGRP can mediate feeding on a 
longer time scale (71-73). 
Opto- and chemogenetic activation of POMC neurons inhibited food intake as predicted. 
Although based on pharmacological experiments this effect might be expected to occur within a 
few hours, constant activation of POMC neurons for 24 hours was necessary before there was 
any measurable difference from controls in food intake or body weight (69,74). Conversely, 
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chemogenetic inhibition of POMC neurons did not measurably increase food intake until it had 
occurred for 24 hours (72). The decrease in food intake upon POMC neuron activation was likely 
due to the release of POMC-derived peptides and the activation of melanocortin receptors, since 
no change in food intake was observed when the experiments were performed in mice 
overexpressing a melanocortin antagonist (69). POMC neurons can also express glutamate or 
GABA but the functional significance is not yet clear (75,76). Preliminary studies have indicated 
that there are two types of neuromodulator release sites, one that releases a combination of 
neurotransmitters and peptides at conventional synapses and other extra-synaptic sites that only 
release peptides (77).  
In light of these exciting new discoveries, it is worth re-examining what has been 
revealed about the neural melanocortin system’s roles in non-feeding behavior as well. In this 
chapter, I will review studies in the literature using genetic knockout models and/or 
administration of melanocortin pharmacological agents that have implicated the neural 
melanocortin system in the regulation of locomotor activity and the HPA axis.  
 
II. Locomotor activity 
 
Energy from consumed food is either used, stored or excreted, and the balance between 
caloric intake and energy expenditure determines body weight. The three main components of 
energy expenditure are basal metabolic rate, the thermic effect of food, and physical activity 
(78). Physical activity levels vary greatly between individuals and are to some extent biologically 
determined, although many of the genes and pathways involved have not yet been identified 
(79).  
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Physical activity can be divided into two categories: Obligatory for survival, such as 
searching for food and avoiding predators, or discretionary. According to a broader definition, 
obligatory activity falls under “spontaneous” or “nonexercise” activities that are associated with 
daily life, whereas discretionary activities are often considered voluntary exercise (80). In 
humans, many activities lie along a spectrum between these two categories and fall into a gray 
area that makes categorization difficult.  
There is a tight negative relationship between body weight and activity levels in both 
humans and rodents (78,81). Often, obesity is assumed to be secondary to low physical activity 
levels, and increasing voluntary exercise is a common first approach to losing body weight in 
obese individuals. However, compensatory decreases in spontaneous activity can occur upon 
increased levels of voluntary exercise, as total energy expenditure varies little day-to-day 
whether or not a person exercises (80). On the other hand, it is equally possible that low physical 
activity levels are a result of obesity. Although both spontaneous and voluntary activity levels 
are believed to be controlled by multifaceted and likely extensively overlapping networks in the 
brain, very little is understood about either. Furthermore, the relationship between obesity and 
activity levels is complex and deserves further study, making the use of animal models 
imperative. 
Laboratory rodents live in a tightly controlled environment with access to only certain 
types of behavior, and the definitions of spontaneous versus voluntary activities have become 
tied to specific measurement protocols. Standard rodent housing affords the opportunity for only 
spontaneous activity, which is measured in a home cage or home cage-like environment using 
infrared beams, force plates or video analysis, and includes locomotor activity as well as 
grooming and rearing (78). Differences in levels of spontaneous home cage activity are believed 
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to be representative of intrinsic differences between individuals in the tendency to be physically 
active. On the other hand, introduction of a running wheel into the standard cage has been argued 
to be representative of voluntary exercise (80). Although spontaneous and voluntary physical 
activity levels, as thus defined, tend to positively correlate across strains, treatment groups and 
genotypes, there is ample evidence that access to a running wheel amplifies activity levels and 
engages reward pathways (82). 
There are some reports that neural circuits involved in feeding can also regulate physical 
activity levels. In keeping with the catabolic and anabolic roles of POMC and AGRP, 
respectively, one might hypothesize that POMC-derived peptides would increase activity levels 
whereas AGRP would decrease them. Here, I will review the literature suggesting a role for the 
neural melanocortin system in control of both spontaneous as well as voluntary activity levels. 
Furthermore, caloric restriction induces a unique behavior termed food anticipatory activity 
whereby an animal displays increased locomotor behavior immediately before it receives a daily 
allotment of food, and the melanocortin system has also been implicated in this behavior.   
      
A. Spontaneous locomotor activity 
 
Pharmacological studies in rats have in general supported the suggestion that POMC 
peptides activate, whereas AGRP inhibits, spontaneous physical activity levels. Acute i.c.v. 
injection of either α-MSH or ACTH dose-dependently increased home-cage grooming, 
locomotion and rearing in male rats for up to 9 hours (83). On the other hand, a single i.c.v. 
injection of AGRP decreased spontaneous home cage locomotion in male rats for up to three 
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days (84). Chronic i.c.v. treatment with a synthetic melanocortin antagonist similarly decreased 
spontaneous locomotion in male rats (85).  
Evidence from genetic knockout models has generally supported these conclusions, but 
interpretation has been difficult because of the obesity in these models. Thus, Pomc-KO mice 
may be expected to have decreased locomotor activity as a direct result of the lack of POMC, but 
they are also morbidly obese which may itself affect activity levels. Separating the primary 
genetic insult from resulting obesity is not a simple task. Indeed, obese mice of both sexes 
lacking Pomc specifically in the Arc exhibited markedly decreased spontaneous locomotion 
which was completely normalized by reactivation of the Pomc gene in adulthood, concomitant 
with a return to normal body weight (34,86). Postnatal ablation of ArcPOMC neurons also 
significantly reduced spontaneous locomotor activity in association with increased body weight 
(74). In both of these studies, changes in activity levels were assumed to be secondary to body 
weight changes but this was not directly studied. 
Several strains of Mc3r-KO mice have been generated, all of which have normal body 
weight but increased adiposity. In the first strain described, males were found to have normal 
spontaneous home cage locomotor activity, whereas females showed somewhat decreased 
activity (27). In the next strain generated, only males were characterized, and they exhibited 
normal spontaneous home cage locomotor activity (87,88). In a more recently described 
reactivateable Mc3r-KO mouse, the knockouts showed a slight decrease in spontaneous 
locomotor activity, but sex was not reported (89). Mc4r-KO mice are obese and both sexes 
exhibited decreased spontaneous locomotor activity (28,90). Interestingly, there is one report that 
young, pre-obese male Mc4r-KO mice had the same spontaneous locomotor activity as wildtype 
controls, suggesting that in this model, low locomotor activity may be secondary to obesity (91).  
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 Agrp-KO mice of both sexes were initially described as having normal spontaneous 
locomotor activity (29), but further investigation revealed a late-onset hyperlocomotion in male 
Agrp-KO mice associated with a lean phenotype (92). This phenotype agrees with the 
pharmacological studies suggesting that AGRP inhibits spontaneous locomotion. In contrast, 
chemogenetic activation of AGRP neurons significantly increased spontaneous locomotor 
activity in mice of both sexes, but only in the fasted state (70,93). This effect could be mediated 
by NPY or GABA rather than AGRP, as one study suggested (93), or it could indicate that the 
role of the neural melanocortin system in control of locomotor activity may be differentially 
regulated by nutritional state.  
 Taken together, the reports of home cage activity of the knockout mouse lines described 
above suggest that the melanocortin system may not play a primary role in spontaneous 
locomotor levels, but that the obesity in these models may lead to decreased activity. However, 
this conclusion has not been thoroughly tested and there is evidence that the melanocortin system 
does regulate activity in other genetic mouse strains. Ob/ob mice are a unique model in that they 
are morbidly obese but the brain perceives a state of starvation due to lack of leptin. These mice 
as well as mice lacking leptin receptor (LepR) displayed low spontaneous home cage 
locomotion. Systemic or i.c.v. infusion of leptin dose-dependently increased, although did not 
totally rescue, home cage activity of male ob/ob mice, but did not affect activity in wildtype 
controls (94,95). The effect of leptin on locomotor activity in ob/ob mice in these experiments 
occurred prior to any measurable decrease in body weight and suggested a primary role for leptin 
in the central control of locomotion in an otherwise hypoleptinemic animal.    
Unilateral virus-mediated reactivation of LepR in the Arc of male Lepr-null mice almost 
completely normalized spontaneous locomotor activity while having little impact on body weight 
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and food intake (96). Genetic restoration of LepR limited to POMC neurons of male mice had 
the same phenotypic effect as whole Arc rescue, suggesting that POMC neurons in the Arc are 
sufficient for this leptin-induced increase of locomotor activity (97). However, as mentioned 
above, the Pomc-Cre mouse line used to generate these results has been shown to transiently 
express Pomc during development in neurons that differentiate into non-POMC neurons, so these 
results should be interpreted with caution. A study using a complementary approach suggested 
that Arc AGRP neurons are also leptin-responsive locomotion-inducing neurons. In this study, 
LepR was deleted in male mice only from AGRP neurons or in both POMC and AGRP neurons, 
and a similar decrease in home cage locomotor activity was observed in both transgenic groups 
(98). Conversely, mice with constitutive activation of Stat3 signaling (one of the major 
downstream pathways of LepR) specifically in AGRP neurons, but not POMC neurons, showed 
increased spontaneous locomotor activity (99). In this study sex was not reported.  
Together these data suggest that leptin signaling onto either POMC or AGRP neurons 
may lead to increased spontaneous locomotor activity in some mouse models independent of 
changes in body weight. Signals other than leptin may also mediate spontaneous physical activity 
levels via the melanocortin system. For example, male mice lacking insulin receptor in the whole 
hypothalamus are lean and hypolocomotive. Re-expression of insulin receptor in only POMC 
neurons, but not AGRP neurons, rescued the locomotor activity levels of these mice (100).  
Possible involvement of the melanocortin system in the locomotor effects of other peripheral and 
central signals is still being explored. However, as alluded to earlier, exploring these pathways 
by utilizing knockout mice should be carefully controlled and interpreted, as deletion of a major 
nutritional signal will likely change the perceived nutritional status of the animal and thus could 
affect behavioral responses.   
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B. Voluntary wheel running activity 
 
Although some controversy surrounds the use of running wheels as a rodent model for 
voluntary exercise, it is currently the best model available. Most laboratory mice and rats readily 
run on wheels provided in the home cage, although some strains show more intrinsic running 
activity than others. As mentioned above, spontaneous home cage locomotion and amount of 
running wheel activity are roughly correlated across strains. In some animals, the introduction of 
a running wheel can intensify total activity levels as evidenced by increased food intake or the 
development of a negative energy balance. In others, a compensatory decrease in spontaneous 
home cage activity can occur and total energy expended in physical activity remains unchanged 
(101). There is a huge level of individual, sex, strain and species variability in the behavioral 
response to a running wheel.  
Although some argue that wheel running may be a stereotypical behavior induced by the 
unnatural environment of laboratory cages, there is extensive evidence that rodents find wheel 
running rewarding. Indeed, even wild mice ran extensively on wheels provided in their natural 
environment (102). Rats showed conditioned place preference for the environment paired with a 
previous running episode and they lever pressed for access to a wheel. Wheel running has been 
shown to decrease motivation for food and drugs such as amphetamines, while conversely food 
deprivation increased lever pressing for both cocaine and access to a running wheel. 
Additionally, running in a wheel is known to activate neural circuitry associated with reward. 
Therefore, running wheel activity, though correlated with spontaneous activity, likely does not 
reflect solely the tendency to be physically active but is also related to motivation and reward. 
Intriguingly, some of the same brain regions seem to be involved in controlling both appetite and 
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reward, and these areas are activated by wheel running. The neurobiological mechanisms 
regulating running wheel activity levels are almost completely unknown, but the dopaminergic 
system tops the list of candidates (103).    
POMC and AGRP neurons are known to lie upstream of various regions of the 
dopaminergic system, including the ventral tegmental area and the nucleus accumbens, which 
abundantly express Mc3r and Mc4r, respectively (104,105). As such, the melanocortin system 
has been suggested to play a role in the rewarding effects of not only food but also alcohol and 
drugs of abuse. That body of literature is outside of the scope of this review, but in general, 
POMC peptides are believed to decrease the rewarding value of food and alcohol reward but 
increase drug reward whereas AGRP does the opposite. However, there are reports published 
that conflict with each of these conclusions. Thus the interaction of the neural melanocortin 
system with the reward system is complex and likely varies for different rewarding stimuli.  
To my knowledge, no groups have reported differences in running wheel behavior after 
acute or chronic injections of melanocortin pharmacological agents. Rather, genetic knockout 
models have been used. As with spontaneous home cage activity, the obesity of these models can 
complicate the studies. Obese, neural-specific Pomc-KO male mice exhibited approximately half 
the amount of running wheel activity as wildtype controls (106). Perplexingly, Mc3r-KO male 
mice have been described as running either the same amount as, or significantly less than, 
wildtype controls by the same group of researchers (26,87-89). Young, preobese Mc4r-KO mice 
of both sexes showed the same voluntary running wheel activity levels as wildtype (107). When 
male Mc4r-KO mice were housed with a running wheel from an early age, they ran the same 
distance as wildtype controls over the course of an 8-week study and, although still slightly 
heavier than wildtype, fat mass, insulin, and leptin levels were normalized (108,109).  
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Together these studies suggest that POMC signaling via Mc3r and/or Mc4r plays either a 
negligible role or no role in direct regulation of voluntary wheel running behavior, and that any 
decrease in running amount seen in these genetic knockout models is secondary to development 
of obesity. However, more complete studies need to be performed, and there is at least one piece 
of evidence to the contrary. Older, slightly obese male rats that were administered a viral vector 
overexpressing Pomc showed increased running wheel activity. These rats also lost weight, but 
the control pair-fed group of rats lost the same amount of body weight and showed no change in 
wheel running activity (110). Furthermore, studies of running wheel activity in mice with altered 
Agrp expression have not been reported to my knowledge. 
   
C. Food anticipatory activity 
 
The light-dark cycle is an important entrainment cue for behavior and physiology. Both 
spontaneous home cage locomotor activity and voluntary running wheel activity occur almost 
exclusively during the night in laboratory rodents, which are nocturnal. However, when 
laboratory rodents are given access to a restricted amount of food for only a few hours during the 
day time, a new rhythm is created. Two hallmarks of this new rhythm are food anticipatory 
activity (FAA), or a marked rise in locomotor activity levels 2-3 hours before presentation of 
food, as well as a coinciding rise in corticosterone. These new rhythms suggest the presence of a 
food entrainable oscillator that is independent of the light-dark oscillator.  
The search for the location and mechanism of the food entrainable oscillator using lesion 
studies and genetic knockout models has been reviewed elsewhere (111,112). Some studies have 
suggested that hypothalamic regions involved in feeding and energy expenditure may also be 
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involved in FAA. This phenomenon has not been well-studied as it relates to the neural 
melanocortin system. If FAA is driven by hunger, one might argue that AGRP, being an 
orexigenic hormone, might increase FAA while POMC might do the opposite. Along these lines, 
mice lacking leptin exhibit increased FAA and administration of leptin blocks FAA (95).  
To my knowledge, FAA has not been studied in genetic knockout models of either Pomc 
or Agrp, but Mc4r-KO mice have been reported to have normal FAA (87). On the other hand, 
and contrary to the above hypothesis, male Mc3r-KO mice exhibited decreased FAA as 
measured both by home cage activity and running wheel activity (87). These results suggest that, 
although melanocortin signaling is not necessary for FAA, it may play a modulatory role on its 
amplitude. On the other hand, further studies suggested that the decreased FAA reported in 
Mc3r-KO mice may be due to an impairment in their ability to adjust to a new schedule because 
FAA levels are only lower than wildtype for the first two weeks of scheduled food restriction 
(88,113). In this case, melanocortins may be involved only in the acquisition but not the 
expression of FAA. 
 
D. Concluding remarks 
  
In synthesizing the results of all of the above-mentioned studies, one may conclude that 
the neural melanocortin system likely does not play a primary role in the control of locomotor 
activity. However, to my mind, the lack of consistent protocols, data collection methods and data 
reporting methods has left this conclusion questionable. Many of the studies mentioned were not 
designed as thorough examinations of physical activity but merely reported locomotor activity as 
part of a broad panel of energy expenditure assays. Additionally, and unfortunately, researchers 
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have often considered home cage activity and wheel running activity interchangeably and only 
reported one or the other. Thus a specific change in either spontaneous or voluntary activity 
levels could have been overlooked. Some groups even use activity in a short time frame upon 
exposure to a novel environment (e.g. open field test) as representative of spontaneous activity, 
but behavior in these situations is more directly related to anxiety or stress, does not correlate 
with either spontaneous or voluntary locomotor activity levels, and was not mentioned here. 
Furthermore, the relationship between obesity and locomotion needs to be investigated more 
thoroughly.  
 
III. Hypothalamic-pituitary-adrenal stress axis 
 
The HPA axis is the endocrine arm of the body’s response to stress, which is broadly 
defined as any real or perceived threat to homeostasis and encompasses a broad range of 
psychological and physiological stimuli. The primary mediators of the HPA response are 
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP), which are synthesized 
in the paraventricular nucleus of the hypothalamus (PVH) (Figure 1.3). CRH and AVP are 
released from axon terminals in the median eminence, enter the hypophyseal portal system and 
bind to CRH receptor 1 and AVP receptor 1b, respectively, on corticotrophs in the anterior 
pituitary. CRH and AVP act synergistically to stimulate production and release of ACTH, which 
enters the bloodstream and binds to melanocortin 2 receptors (Mc2r) on the adrenal cortex. Mc2r 
activation stimulates synthesis and release of glucocorticoids (GCs), which act on glucocorticoid 
receptors (GR) throughout the body to increase energy mobilization, inhibit growth, suppress the 
immune and reproductive systems, and potentiate the other arm of the stress response mediated 
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by the sympathetic nervous system (114). In addition to its important role in the stress response, 
the HPA axis is diurnally regulated whereby a daily rise in GCs occurs at the beginning of the 
active cycle. At low concentrations, such as in the diurnal nadir, GCs can also signal via the 
high-affinity mineralocorticoid receptor (MR).  
Critically, dysregulation of the HPA axis, usually presenting as a chronic elevation in 
GCs, is associated with neuropsychiatric diseases such as depression as well as diabetes and 
metabolic syndrome (115,116). GCs provide negative feedback to the HPA axis at the level of 
the pituitary as well as directly at the PVH (117). Additionally, the PVH receives and integrates 
signals from various brain regions, including the brainstem, limbic regions such as the amygdala 
and hippocampus, as well as other hypothalamic nuclei. Some of these sites stimulate the PVH 
upon exposure to a stressor while some mediate GC-regulated negative feedback (118,119). The 
complex system controlling HPA activation can become dysregulated due to increased central 
drive or decreased negative feedback, which are difficult if not impossible to distinguish from 
each other. Although there are several lines of evidence suggesting extensive crosstalk of the 
neural melanocortin system and the HPA axis, results have often been contradictory or difficult 
to interpret and the precise interaction between the two systems has not been defined. 
 
A. The melanocortin system is downstream of the HPA axis 
 
Stress is believed to affect feeding behavior in two distinct ways, and the neural 
melanocortin system has been implicated in both. An acute stressor results in a rapid decrease in 
food intake which is known as stress-induced anorexia, whereas chronically elevated GCs are 
believed to induce food intake, specifically of palatable or high-energy food (120,121).  
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1. Stress-induced anorexia 
 
Pharmacological studies have indicated that CRH signaling in the brain is necessary for 
stress-induced anorexia (122), and several lines of evidence suggest that the neural melanocortin 
system may be downstream. Within 30 minutes of onset of a stressor, POMC neurons were 
activated and Pomc mRNA levels were increased (123-125). Furthermore, administration of a 
melanocortin receptor antagonist before the stressor ameliorated or eliminated stress-induced 
anorexia, suggesting a role for the melanocortins in this phenomenon (123,126-128). There are 
known direct projections from the PVH to ArcPOMC neurons as well as known relays through 
other candidate nuclei such as the ventromedial hypothalamus (VMH) (60). Glutamatergic 
neurons in the VMH express CRH receptors and project to the Arc. Injection with a CRH agonist 
into the VMH increased Pomc mRNA in the Arc and decreased feeding, suggesting a possible 
indirect route by which POMC neurons are activated by stress (129).  
However, these data are merely correlative. If melanocortin signaling was necessary for 
stress-induced anorexia, one would predict that genetic models of melanocortin deficiency would 
not exhibit the anorectic response. Contrary to this hypothesis, mice that ectopically express the 
melanocortin receptor antagonist agouti in the brain, although in general are hyperphagic, exhibit 
an exaggerated anorectic response to stress (130). In agreement with this, we have observed the 
same phenomenon in mice that lack Pomc specifically from the Arc (unpublished observation). 
Thus the role of melanocortins in stress-induced anorexia is still controversial and under 
investigation.  
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2. Glucocorticoid-induced feeding 
 
A direct orexigenic role for GCs is supported by reports that adrenalectomy induces 
anorexia (131) whereas sub-chronic i.c.v. infusion of GCs into adrenally intact animals increases 
food intake and body weight (132). Indeed, many genetic and pharmacologically-induced rodent 
models of obesity exhibit marked hypercorticosteronemia (133). One of the most extensively-
studied examples is the ob/ob mouse, which genetically lacks the hormone leptin (134). Ob/ob 
mice have increased basal and stress-induced plasma corticosterone (135-137), and 
adrenalectomy normalizes food intake and reduces body weight (138,139). Similar studies on 
other obesity models have led to the conclusion that GCs are necessary for these obesity 
syndromes (140,141).  
A role for the neural melanocortin system in GC-induced feeding has been suggested. 
Ob/ob mice have elevated Agrp mRNA levels, which are reduced by adrenalectomy (138). 
Transgenic mice overexpressing Crh exhibit increased GCs and food intake associated with 
increased Agrp levels (142). In adrenal-deficient mice and following adrenalectomy in rats, 
hypothalamic Agrp mRNA levels were markedly decreased and AGRP neurons were less 
excitable, both of which were reversed by GC administration (143-147). Surprisingly, Pomc 
mRNA levels in the rat hypothalamus were also markedly decreased following adrenalectomy, 
and chronic GC replacement returned these levels to normal (146,148-150). This is in marked 
contrast to the inhibitory effect of GCs on Pomc transcription in the anterior pituitary (151). 
These data suggest that GCs can increase both hypothalamic Agrp and Pomc and suggest that a 
role for melanocortins in GC-induced feeding may be complex.  
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GC-induced feeding is itself a rather complicated and controversial topic. Notably,  ob/ob 
mice, along with other hypercorticosteronemic genetic models of obesity and rats chronically 
administered GCs, are also hyperinsulinemic (132,152). Furthermore, adrenalectomy in normal 
rodents also decreases insulin levels (143). A series of studies on adrenalectomized, insulin-
deficient rats suggest that the interaction of GCs and insulin determines both how much and what 
type of food is consumed (153). Differentiating the specific roles and interactions of GCs and 
insulin has proven extremely challenging. Some researchers have concluded that GCs are 
permissive, but not causative, for hyperphagic obesity (154). Nonetheless, taken together the 
above-mentioned studies suggest that the melanocortin system can be regulated by GCs. Most, if 
not all, POMC and AGRP neurons express GR, suggesting that this effect could be direct, 
although this has not been well-studied (155,156).  
 
B. The melanocortin system is upstream of the HPA axis 
 
Obesity is associated with hyperactivation of the HPA axis. Although elevated GCs are 
often viewed as causative in the development of obesity, it is also plausible that energy status 
and the pathways involved in feeding and energy homeostasis could affect the HPA axis (157).  
 
1. Pharmacological studies 
 
Preliminary evidence that energy pathways affect the HPA axis came from rats treated 
neonatally with monosodium glutamate, which lesions the arcuate nucleus (158). The 
hypothalamus and anterior pituitary of MSG-treated rats are hyperresponsive to a variety of 
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stimuli, and specifically MSG-treated rats exhibited elevated ACTH and GCs both basally and 
following stress (159,160). Together with the fact that ob/ob mice exhibit the same phenotype, 
the MSG studies suggest that a leptin-responsive Arc population of neurons exhibits a net 
inhibitory effect on the HPA axis. Both POMC and AGRP neurons project directly to the PVH 
as well as to candidate relay nuclei such as the amygdala and the bed nucleus of the stria 
terminalis (60). Chronic implantation of an ACTH pellet into the median eminence, but not the 
pituitary, decreased corticosterone in rats (161), and ACTH and α-MSH dose-dependently 
decreased CRH release from hypothalamic slices in vitro (162,163). Furthermore, endogenous α-
MSH inhibited activation of the HPA axis induced by interleukin-1β injection (164,165). 
Additionally, melanocortin signaling must be intact for rescue of elevated GCs caused by 
induction of diabetes (166). Thus, activation of melanocortin receptors can inhibit the HPA axis.  
However, and in stark contrast to the studies mentioned above, acute i.c.v. injection of 
ACTH, α-MSH or the synthetic Mc3r/Mc4r agonist melanotan II (MTII) have been shown to 
increase plasma GCs as well as exaggerate the HPA response to stress (167-171). Approximately 
20% of CRH neurons express Mc4r, and i.c.v. MTII or α-MSH increased Crh mRNA levels in 
the PVH, suggesting a direct route of activation of the HPA axis by melanocortins (170,172). 
Furthermore, administration of the Mc3r/Mc4r antagonist HS014 attenuated the rise in GCs 
following acute stress (128,173). Surprisingly, intra-PVH injection of either NDP-MSH, a long-
acting α-MSH analogue, or AGRP led to equal rises in plasma ACTH and GCs, in contrast to the 
opposite effect that these two peptides have on feeding and energy balance (174). These studies 
suggest that acute activation of the entire melanocortin system can activate the HPA axis. 
There are problems inherent in each approach to understanding the cross-talk of the 
melanocortin and HPA systems. MSG treatment has been shown to not only lesion the Arc but 
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also affect the VMH and suprachiasmatic nucleus (175). As in any pharmacological study, 
dosage and potency of the drugs administered is of tantamount importance to consider. Indeed, 
one study found that although a fairly “standard” dose of α-MSH administered i.c.v. increased 
plasma GC levels, a dose ten times lower actually inhibited the HPA response to an 
immunological stressor (165). The specific drug used also matters crucially as some synthetic 
melanocortin agonists are much more potent than endogenous ligands. All too often, these 
considerations are not tested and could lead to the discrepant results described here.  
 
2. Genetic studies 
 
One approach to probe the role of endogenous melanocortins in the HPA axis is to 
examine genetically engineered mouse models. Agrp-KO mice, as mentioned above, have no 
metabolic phenotype, which suggests either developmental compensation or a predominant role 
for other neuromodulators produced by AGRP neurons (29). In keeping with the relative lack of 
abnormal phenotype, Agrp-KO mice have normal basal GC levels (176). Postnatal ablation of 
AGRP neurons, which led to anorexia, did not affect GC levels as measured 48 hours after 
ablation (64). Further, although some CRH neurons express Mc4r, no synaptic connectivity of 
these neurons with AGRP neurons could be detected (73). Most studies, including all chemo- 
and opto-genetic studies of AGRP neurons published thus far, either did not measure or did not 
report any readout of HPA function. Thus although what has been reported does not absolutely 
exclude a role for endogenous AGRP in regulation of the HPA axis, there is as of yet no direct 
evidence that it has one.  
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The HPA axis of both Mc3r-KO and Mc4r-KO mice has not been well characterized 
beyond the report of normal basal GCs at the diurnal nadir (25,27). Similarly, Mc4r-KO rats 
have unchanged basal plasma GCs both at the diurnal nadir and peak, but they show a reduced 
HPA response to restraint stress (177). This suggests that the mouse knockout models of the 
melanocortin receptors may also have a non-obvious HPA phenotype. 
The use of genetic mouse models to explore a role for neuronal POMC in regulation of 
the stress axis has been complicated by the critical role of peripheral POMC in the HPA axis. A 
gain of function approach was to transgenically overexpress only the N-terminal portion of the 
Pomc gene that includes α- and γ-MSH. These mice had normal basal plasma GCs but had 
significantly lower GCs than controls when challenged with a high-fat diet, suggesting that under 
metabolic challenge α-MSH can inhibit the HPA axis (178). 
Two Pomc-KO mouse strains have been generated by separate laboratories (23,24). The 
adrenal glands do not develop properly postnatally secondary to the absence of circulating 
ACTH, and Pomc-KO  mice have no measurable circulating GCs either basally or upon 
stimulation by a stressor (4,179). Similarly, postnatal POMC ablation leads to destruction of the 
corticotrophs and complete loss of GCs (64,180). In an effort to separate the role of POMC in the 
pituitary versus the hypothalamus, one group specifically ablated hypothalamic POMC neurons 
via stereotaxic injection and reported a decrease in fasting GC levels (74). Similar to AGRP, I 
could not find data reporting any HPA axis changes in mice that had POMC neurons chemo- or 
optogenetically activated or inhibited.  
To specifically study the role of POMC in the hypothalamus, the Low laboratory crossed 
Pomc-KO mice with mice engineered to carry a transgene directing Pomc expression only to 
pituitary cells but not to neurons, effectively creating a neuron-specific Pomc-KO (181). In this 
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model, the diurnal rhythm of GCs was preserved but corticosterone levels were elevated over 
controls (181). This was associated with increased area of the adrenal cortex and increased 
mRNA levels of Crh in the PVH (182). These data suggested a role for hypothalamic POMC in 
inhibition of the HPA axis, but presence of the Pomc-KO allele was associated with development 
of late-onset pituitary adenomas, complicating the interpretations. Additionally, opioids are 
known to have an inhibitory role on the HPA axis, and β-endorphin is one of the cleavage 
products of the POMC propeptide (183). However, the HPA axis of β-endorphin-KO mice was 
completely normal, leading me to believe that any HPA phenotype in neural-Pomc-KO mice is 
due to loss of melanocortin signaling (184).  
 
C. Concluding remarks 
 
The relationship between the neural melanocortin system and the HPA axis is extremely 
complex and warrants further investigation. Although it has not been definitively proven, the 
neural melanocortin system could be directly and immediately activated by a stressor and play a 
role in stress-induced anorexia. On the other hand, melanocortins could be dysregulated by 
chronically high GCs and lead to excessive feeding behavior. Further, there is evidence that the 
melanocortin system could activate or inhibit the HPA axis. It is likely that the specific pathway 
activated could depend on the type and timing of the stressor as well as the physiological state of 
the organism. Much more work will be needed to unravel the precise interplay between the 
neural melanocortin system and the HPA axis.  
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IV. Conclusions and Future Directions 
 
The neural melanocortin system has been shown to play a critical role in feeding 
behavior, energy expenditure, energy partitioning, cardiovascular health, the immune system, 
and sexual function. Here I have reviewed some accumulating evidence that it may also be 
involved in the regulation of locomotion and in control of the HPA stress axis. Overall, the 
consensus in the field currently is that neural melanocortins may induce locomotor activity via 
Mc3r specifically in cases of food restriction but otherwise are not critically and directly 
involved in physical activity levels. Additionally, although there is evidence that melanocortins 
could inhibit the HPA axis, the preponderance of evidence suggests that, at least acutely, they 
stimulate it. 
Most of the studies probing these roles have measured behavior or physiology after 
administration of exogenous melanocortin ligands or in the melanocortin receptor knockout 
animals. A large and missing piece of the puzzle is the phenotypic characterization of a mouse 
model that selectively lacks endogenous neural melanocortin agonists. The Low and Rubinstein 
laboratories have identified two upstream enhancer regions necessary to drive Pomc expression 
specifically in the Arc (185). Upon insertion of a neomycin resistance cassette into this enhancer 
region, Pomc expression is completely ablated in the Arc but left intact in the pituitary (86) 
(Figure 1.4). These ArcPomc-KO mice phenocopy the previously generated neuron-specific 
Pomc-KO mice described above in that they are morbidly obese due to a combination of 
hyperphagia and reduced energy expenditure, but no ArcPomc-KO mouse has been observed to 
develop pituitary tumors.  
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Systematic characterization of spontaneous home cage locomotor activity and voluntary 
wheel running activity in obese ArcPomc-KO mice and weight-matched knockouts will help to 
definitively prove whether and how POMC controls activity levels. Further, calorically 
restricted, weight-matched knockouts will provide an ideal opportunity to study the role of 
POMC in food anticipatory activity (See Chapter 2). An in-depth examination of the HPA axis of 
this novel genetic model will also help to identify the role and mechanism of ArcPOMC in the 
regulation of the HPA axis (See Chapter 3). One shortcoming of many previously-published 
reports is that only one sex is studied and, sometimes, sex is not even reported. Sex affects 
physiology and behavior and is especially relevant in the study of every aspect of 
neuroendocrinology. Therefore, in this report, we have studied each sex separately and speculate 
on the mechanism and significance of identified sex differences. 
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Figure 1.1: Proopiomelanocortin peptide processing in the anterior pituitary and arcuate 
nucleus. ACTH: adrenocorticotropic hormone; LPH: lipotropic hormone; MSH: melanocyte-
stimulating hormone; CLIP: corticotropin-like intermediate peptide.
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Figure 1.2: Classic model of the neural melanocortin system. LepR: Leptin receptor; 
POMC: Proopiomelanocortin; AGRP: Agouti-related peptide; Mc3r: Melanocortin-3 receptor; 
Mc4r: Melanocortin-4 receptor; Y1r: Neuropeptide Y-1 receptor; GABA-R: Gamma-
aminobutyric acid receptor. 
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Figure 1.3: Diagram of the hypothalamic-pituitary-adrenal stress axis. PVH: Paraven-
tricular nucleus of the hypothalamus; CRH: Corticotropin-releasing hormone; AVP: Arginine 
vasopressin; CRH-R1: CRH-Receptor 1; V1bR: Vasopressin receptor 1b; ACTH: Adrenocorti-
cotropic hormone; Mc2R: Melanocortin-2 receptor: GCs: Glucocorticoids.
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Figure 1.4: Schematic of WT and ArcPomc-KO alleles. A, Two upstream enhancers (nPE: 
neural Pomc enhancer) drive expression of Pomc in the arcuate but are not necessary for 
expression of Pomc in the anterior pituitary. B, Insertion of a neomycin resistance cassette into 
nPE1 and deletion of nPE2 completely abolishes arcuate expression of Pomc but does not 
affect expression in the anterior pituitary. Blue circle: Pomc promoter; White triangles: LoxP 
sites. 
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Chapter 2: Arcuate Proopiomelanocortin Influences Voluntary Locomotor 
Activity Levels Independently of its Role in Food Intake† 
 
Obesity in humans and rodents is associated with decreased physical activity levels. Inactivity 
may be caused by obesity or by environmental and/or genetic mechanisms and in turn contribute 
to obesity. Proopiomelanocortin (Pomc)-expressing neurons in the arcuate nucleus of the 
hypothalamus (Arc) are critical for body weight regulation, controlling both food intake and 
energy expenditure. ArcPomc-knockout (KO) mice are morbidly obese, complicating studies to 
characterize a possible role for ArcPomc in locomotor activity. In this study, we measured both 
spontaneous home cage as well as voluntary running wheel activity levels in obese ArcPomc-KO 
mice and knockouts weight-matched to wildtype controls by caloric restriction.  We found that 
obese ArcPomc-KO mice exhibit decreased home cage locomotor activity which was normalized 
by weight-matching. In contrast, ArcPomc-KO mice exhibited less voluntary running wheel 
activity than controls, regardless of their body weight. Thus we have dissociated these two types 
of locomotor activity and determined that decreased home cage activity in ArcPomc-KO mice is 
secondary to hyperphagic obesity, but ArcPomc plays a primary role in regulation of voluntary 
running wheel behavior.  
_______________________ 
† Data from Figures 2.4 and 2.5 and Table 2.2 were collected in collaboration with Dr. Miho 
Yamashita. Data from Figure 2.6 and Table 2.3 were collected in collaboration with Samantha 
Spierling. All of the work presented in Figure 2.8 was performed by Samantha Spierling under 
my direct instruction and supervision. Mouse colony maintenance and genotyping were 
performed by Jared Goldberg, Courtney Attard, and Eva Yokosawa. 
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Introduction 
 
Obesity is a major worldwide health problem that is strongly associated with a number of 
comorbid conditions, including type 2 diabetes mellitus and cardiovascular disease. Obesity 
results from a positive energy balance created by increased food intake and/or decreased total 
energy expenditure (TEE). Basal metabolic rate, the thermic effect of food, and physical activity 
all contribute to TEE. Intrinsic physical activity levels are highly variable across individuals and 
are at least partially determined by genetic factors. The recent rise in obesity rates in humans has 
been accompanied by a decrease in physical activity levels, but the directionality of this 
relationship is unclear (78,79). Decreased physical activity and the resulting decrease in TEE 
could contribute to the development of obesity, but obesity in itself, regardless of its etiology, 
could also negatively affect physical activity levels (81).  
Mice are a genetically tractable model well-suited to studying the roles of specific genes 
in the relationship between decreased activity levels and obesity, which are also highly correlated 
in mice (81). Many researchers have reported decreased locomotor activity levels in various 
genetically obese mouse models, but the direction of causation is often not investigated. 
Additionally, few groups have considered that laboratory mice are usually housed in an 
unnatural, small environment with little opportunity to engage in physical activity. Indeed, total 
physical activity can be divided into two categories: spontaneous, non-exercise activity or 
voluntary exercise (78,80). Mice in a typical home cage environment can only engage in 
spontaneous activity such as locomotion around the cage and grooming, whereas activity on a 
running wheel introduced into the home cage is believed to be representative of voluntary 
exercise (80). Levels of spontaneous home cage activity and voluntary running wheel activity 
usually correlate positively across mouse strain and sex, but access to a running wheel amplifies 
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activity levels and engages reward pathways (82). Very little is known about the neural and 
endocrine mechanisms regulating either type of activity, but there is evidence that they overlap 
extensively not only with each other, but also with pathways that regulate feeding behavior (78-
80).   
Proopiomelanocortin (POMC) is a propeptide expressed primarily in the pituitary and the 
arcuate nucleus of the hypothalamus (Arc), where its role in feeding behavior has been 
extensively studied. POMC is cleaved in a site-specific manner into the melanocortins α-
melanocyte stimulating hormone (MSH), γ-MSH, and adrenocorticotrophic hormone (ACTH), as 
well as the opioid peptide β-endorphin. Mice lacking POMC specifically in the Arc (ArcPomc-
KO) develop morbid obesity associated with both increased food intake and decreased 
spontaneous home cage locomotor and voluntary running wheel activity (86,106). When the 
Pomc gene was reactivated in obese ArcPomc-KO mice, food intake decreased and body weight 
returned toward that of wild-type (WT). In conjunction, spontaneous locomotor activity was 
normalized (86). However, whether this change was caused by the rescued Pomc gene activity 
independently of obesity or was a secondary effect of the return to normal body weight was not 
determined.  
In the brain, melanocortins activate the melanocortin receptors Mc3r and Mc4r, which are 
antagonized by agouti-related peptide (AGRP), produced in neighboring neurons in the Arc. 
Central injection of melanocortin agonists increased, whereas antagonists decreased, 
spontaneous home cage locomotion in rats (83,84). Mc3r-KO mice, which have normal body 
weight but an increased fat to lean mass body composition ratio, showed decreased spontaneous 
and voluntary locomotor activity levels (26,27,89), although there have also been reports to the 
contrary (87,88). On the other hand, young, pre-obese Mc4r-KO mice showed normal levels of 
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spontaneous locomotor activity, whereas obese Mc4r-KO mice were hypolocomotive (28,91). 
Interestingly, providing Mc4r-KO mice access to a running wheel significantly improved their 
body weight and metabolic outcome (108,109).  
Therefore, we hypothesized that melanocortin signaling influences physical activity 
levels directly as well as indirectly via its effects on body weight. To test this hypothesis, we 
measured spontaneous home cage locomotor activity and running wheel activity of obese 
ArcPomc-KO mice and WT controls as well as ArcPomc-KO mice weight-matched to the 
controls. Many studies mentioned above reported data only from males, whereas we performed 
these experiments in both sexes. We determined that ArcPomc is not necessary for the 
expression of spontaneous home cage locomotion, because weight-matched ArcPomc-KO mice 
showed the same activity levels as their WT controls. On the other hand, ArcPomc regulates 
voluntary running wheel activity independently of obesity, particularly in females. We also 
describe a modulatory role for ArcPomc in determining the amplitude of food anticipatory 
activity specifically in males.    
 
Materials and Methods 
 
Animals. Mice were housed in ventilated cages under controlled temperature (72 ± 2°F) 
and lighting conditions (12 hour light:dark cycle with lights on 6:00 a.m. to 6:00 p.m.). 
ArcPomc-KO mice, also called fneoΔ1Δ2 (86,186), and β-endorphin-KO mice (184) were 
generated as described previously. In both cases, heterozygote pairs were bred to produce KO 
mice and their control wild-type (WT) littermates, and each sex was studied separately. Ad 
libitum-fed mice had free access to water and standard laboratory chow (LabDiet 5L0D). Food-
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restricted mice had free access to water but were administered a pre-weighed pellet of chow 
daily as described below. All animal studies were approved by the University Committee for Use 
and Care of Animals at the University of Michigan and followed the Public Health Service 
guidelines. 
 
Home cage activity. WT and ArcPomc-KO mice (n = 8 per sex and genotype) that had 
previously been group-housed were singly-housed for one week starting at age 18-19 weeks. At 
age 20 weeks, each home cage, with a water bottle and a surplus of food on the cage floor, was 
placed into the center of a 41 x 41 cm open field chamber and horizontal distance traveled per 
minute was recorded by infrared beam breaks using Activity Monitor software (Med Associates) 
for 23 hours each day for 3 days. During the 24th hour, the software was reset and the mice 
weighed to monitor health. Data from the 1st day was considered acclimation and data from the 
second two days was averaged and reported. Following ~10 weeks of food restriction (see 
below), this test was repeated with the modification that the daily food was given by gently 
removing the lid and placing the chow on the cage floor during data acquisition. For food 
restriction, WT mice were maintained at 85% of their starting body weight for 10 weeks by 
giving each mouse 2-3 g of chow per day whereas ArcPomc-KO mice were brought down to the 
starting weight of the WT littermate controls over the course of 10 weeks by giving each mouse 
1.5-2.5 g of chow per day. Food was provided daily at 10:00 am.  
The presence of the home cage occasionally triggered a glitch in the monitoring software 
whereby the mouse appeared to “teleport” across the cage. To correct for this, a Matlab program 
was created to omit data in any 1-minute bin in which the velocity of the mouse was calculated 
by the software to be zero but a distance was nevertheless reported. Additionally, any 1-minute 
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bin in which the mouse was reported to be continuously active for more than 40 s was excluded. 
This time was based empirically on the amount a mouse was deemed likely to run continuously 
upon sensitization to morphine (see below). 
 
Running wheels. Following weaning at 3 weeks of age, a separate cohort of mice was 
group housed for one week and then singly-housed on aspen bedding starting at age 4 weeks in a 
standard home cage either with or without a low-profile wireless running wheel (Med 
Associates). β-endorphin-KO and WT control mice were fed ad libitum and assigned either a 
running wheel or no wheel. ArcPomc-KO mice were assigned to ad libitum feeding with a wheel 
or no wheel or to restricted feeding with a wheel (n = 5-7 per genotype, sex and condition). Each 
radiotelemetric wheel transmitted the number of revolutions per minute to a computer in the 
adjacent room, where data were collected for 3 nights and 2 days, then averaged, each week from 
age 5 to 11 weeks. Mice continued to have access to the wheel after 11 weeks but the data were 
not analyzed because running activity was affected by further tests performed on the mice (see 
below). Mice with ad libitum access to food were weighed once per week and provided a 
preweighed quantity of chow. Uneaten chow was weighed twice per week and the average daily 
intake calculated. Food-restricted, weight-matched (WM) ArcPomc-KO mice were weighed 
once per day at approximately 4:00 p.m., and sufficient food was administered to maintain the 
ArcPomc-KO mice at the same weight as the WT controls. 
 
Metabolic Phenotyping. At age 12-14 weeks, body composition of the mice in the 
running wheel study was analyzed by the University of Michigan Animal Phenotyping Core by 
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nuclear magnetic resonance (NMR) using a Minispec LF90II (Bruker). Fat, fluid and lean mass 
for each animal were expressed both in absolute mass and as percentages of total body weight.  
At age 13-15 weeks, mice underwent an intraperitoneal glucose tolerance test (ipGTT). 
After an 18-hour fast, tails were nicked at 9:00 a.m. and approximately 10 μL whole blood was 
collected. Fasting blood glucose was measured with a glucometer (AlphaTrak, Abbott) and then 
plasma was separated by centrifugation and stored at -20°C for insulin measurement. Meanwhile, 
2 mg/kg glucose was administered i.p. and blood glucose was monitored at regular intervals for 4 
hours. Area under the curve (AUC) was calculated using Prism 6 (GraphPad) assigning each 
mouse its own baseline (blood glucose at time 0). Plasma insulin was measured by an ultra-
sensitive ELISA (Crystal Chem, Inc.).  
At age 14-16 weeks, mice were fasted from 9:00 a.m. to 3:00 p.m. and then euthanized 
by decapitation. Trunk blood was collected into tubes with 10 μL of 75 ng/mL EDTA, and 
plasma was separated by centrifugation and stored at -20°C until analysis for total cholesterol by 
the Chemistry Core of the Michigan Diabetes Research Center.  
 
Semi-quantitative real-time PCR. Following euthanasia, the hypothalamus of the running 
wheel mice was dissected, snap frozen on dry ice, and stored at -80°C. A separate cohort of adult 
group-housed female mice (6-8 month old, N = 8 per genotype) was euthanized by decapitation, 
the brain dissected and two blocks of the brain were microdissected, one containing the ventral 
tegmental area (VTA) and substantia nigra (SN) and another containing the nucleus accumbens 
(NAcc), and stored at -80°C. The VTA/SN and NAcc blocks were separated bilaterally and one 
half was used for analysis. After pretreatment with Qiazol Lysis Reagent (Qiagen), RNA was 
extracted from all tissues using RNeasy spin columns (Qiagen) and any contaminating DNA was 
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removed via Turbo DNase treatment (Life Technologies). Total RNA was quantified and 
quality-checked via NanoDrop (ThermoScientific). Reverse transcription was performed to 
produce cDNA from 400 ng total RNA using random hexamer primers (Goscript RT System, 
Promega). Real-time PCR was performed on all samples in duplicate using the StepOne Real 
Time PCR System (Applied Biosystems) and SYBR Green Master Mix (Life Technologies). 
Primers as listed in Table 2.1 were designed using Primer3 (187) to span at least one intron, 
when possible, and were used at a final concentration of 300 nM. The relative quantity of mRNA 
in the samples was calculated from a standard curve spanning 1000-fold change, normalized to 
reference gene Gapdh (hypothalamus, VTA/SN) or Ppia (NAcc) and then normalized to WT 
controls with no running wheel access. Occasional outliers were identified using Grubbs’ outlier 
test and removed.      
 
Morphine sensitization. An additional cohort of 5-9 month old group-housed mice were 
used to test locomotor sensitization to morphine (n=6 per sex, genotype and drug treatment; 
subsequently, data from males and females were collapsed for statistical analysis). The 
sensitization test was conducted over 11 consecutive days. On each day, each mouse was placed 
into a 41 x 41 cm open field chamber and its locomotor activity recorded by Activity Monitor 
software (Med Associates) for one hour. The first day served to acclimate the mice to the open 
field. The second day, each mouse was injected i.p. with 0.9% saline (WT: 10 μL/g body weight; 
ArcPomc-KO: 5 μL/g body weight) immediately prior to being placed in the open field. 
Following the saline day, mice of each genotype were randomly assigned to either the saline 
control group or the morphine group. On days 1-4, the saline control group was injected with 
saline as above, whereas the morphine group was administered 10 mg/kg morphine (National 
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Institute on Drug Abuse). Following a three day break, each mouse was administered 10 mg/kg 
morphine. On the last day, to test for sensitization to the environment, all mice were injected 
with saline.  
 
Immunohistochemistry. At age 6 months, a separate group of female mice (n=6 per 
genotype) were deeply anesthetized with 2% tribromoethanol i.p. and perfused transcardially 
with 10% sucrose followed by 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) 
on a pressurized rig (Perfusion One; Leica). The brain was dissected and postfixed overnight in 
4% PFA at 4°C then incubated in successive gradients of sucrose (10%, 20%, 30%) in KPBS at 
4°C. Brains were sectioned coronally at 30 µm using a freezing microtome stage (SM 2010R, 
Leica) and stored in cryoprotectant solution (25 mM PBS with 30% ethylene glycol and 20% 
glycerol) at -20°C until use. Free-floating sections were washed three times in KPBS for 15 
minutes per wash and then incubated overnight at 4°C in KPBS with 0.3% Triton X-100 (KPBS-
T), 2% normal donkey serum and monoclonal mouse anti-tyrosine hydroxylase (TH) (1:500, 
Immunostar). Following three more washes, sections were incubated for two hours in donkey 
anti-mouse-AlexaFluor 488 (1:500, Invitrogen) in KPBS-T at room temperature. After three 
more washes, the sections were mounted on gelatin coated glass slides and cover slipped using 
polyvinyl alcohol mounting medium (Sigma Aldrich).  
 
Imaging and Analysis. Sections were imaged using a Nikon 90i upright microscope 
equipped with an X-Cite 120Q fluorescent light source and CoolSNAP HQ2 CD camera 
(Photometrics) and a 4X objective. TH-labeled sections were imaged using a 488 excitation/525 
emission filter cube and 900 ms exposure time. Each CNS nucleus was imaged utilizing rostral-
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caudal coordinates obtained from the Mouse Brain Atlas (188). Coordinates for our nuclei of 
interest were Bregma -2.70 to -3.88 (substantia nigra pars compacta) and Bregma -2.80 to -3.16 
(ventral tegmental area). All post-image analyses were performed in NIS-Elements AR (Nikon), 
and each nucleus was defined by a manually outlined region of interest (ROI). Images were set 
to the same pixel intensity to create a detectable signal in control animals. To quantify 
fluorescence of TH signal, presented in arbitrary units (AU), the mean pixel intensity from each 
ROI was multiplied by the ROI’s binary area. 
 
Statistical analysis. All data are presented as mean ± SEM. Males and females were 
analyzed separately, except in the morphine sensitization study where the sexes were combined. 
Home cage locomotion distances were analyzed by repeated measures ANOVA (RMANOVA) 
with genotype and nutritional status as the independent variables. Running wheel activity and 
body weight were also analyzed by RMANOVA with group and age as the independent 
variables. A significant interaction was followed by Sidak’s multiple comparisons post hoc tests. 
Food intake, body composition, fasting blood glucose, glucose tolerance AUC, fasting plasma 
insulin, total cholesterol, and qPCR results (except those in Figure 2-8) were analyzed by one-
way ANOVA followed by Dunnett’s multiple comparisons tests to compare all groups to WT 
without a wheel and/or to ArcPomc-KO without a wheel. Distance traveled in the morphine 
sensitization study was analyzed using two-way ANOVA followed by Tukey’s multiple 
comparisons post hoc tests. qPCR and IHC data presented in Figure 2-8 were analyzed by 
unpaired Student’s t-test between genotypes. All analyses were performed in Prism 6 
(GraphPad).  
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Results 
 
ArcPomc-KO mice exhibit decreased spontaneous home cage locomotion secondary to obesity.  
 At age 20 weeks, ad libitum-fed ArcPomc-KO mice of both sexes were morbidly obese, 
as described previously (86) (Figure 2.1A). Total spontaneous home cage locomotor activity of 
obese ArcPomc-KO mice over 24 hours was markedly decreased from WT (Figure 2.1B). 
Following 10 weeks of caloric restriction, ArcPomc-KO mice weighed the same as the starting 
weight of WT controls, whereas the WT controls weighed 85% of their starting weight (Figure 
2.1A). Weight-matching ArcPomc-KO mice increased their spontaneous 24-hour home cage 
activity to an equal level as the ad libitum-fed WT controls (Figure 2.1B). In females, food 
restricted WT and ArcPomc-KO mice exhibited identical activity levels. In males, WT mice 
increased their activity levels after caloric restriction and therefore still had higher levels than 
ArcPomc-KO mice.  
 Laboratory mice are nocturnal, and most spontaneous home cage activity occurs in the 
dark hours. Indeed, this is what we found in ad libitum-fed WT mice of both sexes (Figure 2.2). 
The deficit in spontaneous activity levels of obese ArcPomc-KO mice described in Figure 2.1B 
was completely due to decreased activity at night, as there were no differences between 
genotypes during the day. In WT mice of both sexes, nocturnal activity decreased with food 
restriction. In contrast, the nocturnal activity of ArcPomc-KO mice increased with food 
restriction such that, in food restricted mice, there was no difference in nocturnal activity levels 
between genotypes (Figure 2.2A). In both genotypes, day-time activity increased with food 
restriction. In females, this increase was of the same magnitude in both genotypes whereas it was 
somewhat blunted in ArcPomc-KO male mice (Figure 2.2B).  
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 ArcPomc-KO male mice have impaired food anticipatory activity independent of obesity. 
 Restricting food access to a certain period only in the daytime is known to disrupt 
circadian locomotor activity patterns. Specifically, there is a burst in locomotor activity in the 2-
3 hours immediately prior to food presentation which has been termed food anticipatory activity. 
Hourly analysis of spontaneous home cage activity revealed that ad libitum-fed WT mice 
showed two typical nocturnal bursts of activity, one at the beginning and one at the end of the 
dark cycle, and very little activity in the day time (Figure 2.3A). Obese ArcPomc-KO mice also 
showed the same pattern although the activity levels were severely blunted, especially in 
females. Upon food restriction, WT mice of both sexes maintained the burst of activity at onset 
of night but additionally showed a much larger spike anticipating the time of food presentation 
(Figure 2.3B). Weight-matched ArcPomc-KO mice also showed this second, food-entrained 
spike in activity levels, but the amplitude was blunted selectively in males.  
 
Running wheel access slightly improves body weight and body composition in obese ArcPomc-
KO mice  
Reasoning that low activity levels appeared to be secondary to obesity in ArcPomc-KO 
mice, we postulated that giving these mice an opportunity to increase activity levels by providing 
a running wheel in the home cage from weaning onward might delay, improve, or prevent 
obesity. Indeed, ArcPomc-KO mice given access to a running wheel had mildly improved body 
weight, but the effect was not as large as anticipated, especially in females (Figure 2.4A). The 
body weight of WT mice with a wheel was not different from WT without a wheel.  
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We also performed metabolic phenotyping of these mice at the end of the study. In WT 
mice of both sexes, access to a running wheel did not change body composition, fasting blood 
glucose or glucose tolerance, or fasting plasma insulin or cholesterol levels (Table 2.2). Obese 
ArcPomc-KO male mice with access to a running wheel had improved body composition, as 
percentage of lean body mass was increased and percentage of fat body mass was decreased 
from obese ArcPomc-KO mice without a wheel, although body composition was still different 
from WT controls. Additionally, obese ArcPomc-KO male mice with a wheel had normalized 
levels of total plasma cholesterol (Table 2.2A). In females, obese ArcPomc-KO mice with access 
to a wheel did not have an improved metabolic phenotype over ArcPomc-KO mice without a 
wheel (Table 2.2B).  
On the other hand, weight-matching ArcPomc-KO mice of both sexes to WT controls 
normalized fasting blood glucose, glucose tolerance, fasting plasma insulin and total cholesterol 
levels. Weight-matching ArcPomc-KO also improved body composition and absolute lean mass, 
expressed in grams, was not different from WT. However, weight-matched ArcPomc-KO mice 
still had more fat mass than WT and therefore a decreased percentage of lean mass and increased 
percentage of fat mass (Table 2.2).   
 
ArcPomc-KO mice show low levels of voluntary running activity independent of obesity. 
In WT mice of both sexes, wheel running activity at the beginning of the study was 
relatively low and increased over a period of 2-3 weeks until it plateaued (Figure 2.4B). In ad 
libitum-fed ArcPomc-KO mice, the running wheel activity at age 5 weeks was the same as WT 
but rather than increasing and plateauing, activity levels gradually decreased with age and 
became less than WT by age 8 weeks in males and 7 weeks in females (Bonferroni’s multiple 
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comparisons test, P < 0.05). ArcPomc-KO mice weight-matched to WT from weaning increased 
running wheel activity similarly to WT in the beginning of the study but activity levels dropped 
off and were less than WT by age 8 weeks in females and age 11 weeks in males (Figure 2.4B) 
(Bonferroni’s multiple comparisons test, P < 0.05).  
At age 5 weeks, the total amount of running wheel activity was not different between the 
groups, and all mice ran on the wheels almost exclusively at night (Figure 2.5A). By the end of 
the study, both obese and weight-matched ArcPomc-KO mice of both sexes showed significantly 
less running wheel activity at night than WT controls (Figure 2.5B). On the other hand, weight-
matched ArcPomc-KO mice ran more on the wheels during the day time. In this study, mice 
were fed at approximately 4:00 pm, so this shift in running rhythm is likely correlated with food 
anticipatory activity.  
To test for a role of β-endorphin, one of the cleavage products of the POMC peptide, in 
regulation of running wheel activity, we repeated this experiment in β-endorphin-KO mice. 
Throughout the duration of the study, β-endorphin-KO mice of both sexes showed the same level 
of 24-hr voluntary wheel running activity as their WT littermate controls (Figure 2.6A). 
Additionally, there were no differences between WT and β-endorphin-KO mice in the diurnal 
pattern of running activity at the end of the study (Figure 2.6B).  
 
Repeated morphine administration to obese ArcPomc-KO mice increases locomotor activity to 
the same level as WT.  
 To confirm the physical ability of obese ArcPomc-KO mice to run and to ascertain if 
brain reward circuitry was intact, we next performed a morphine sensitization study. When 
injected with saline immediately before being placed in an open field to which they had been 
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acclimated the previous day, ArcPomc-KO mice had markedly decreased locomotor activity 
compared to WT (Figure 2.7A,B). However, when injected with morphine, both WT and 
ArcPomc-KO mice increased the distance traveled in the open field to the same level (Figure 
2.7A). The locomotor sensitization effect of morphine was measured by comparing the distance 
traveled on the first and last day of repeated morphine injection, and both genotypes showed 
sensitization (WT: t(11) = 2.8, P < 0.05; ArcPomc-KO: t(11) = 5.1, P < 0.001; paired Student’s 
t-test). Because baseline activity levels were different between genotypes, we normalized the 
distance traveled to the average for each group on the saline day. According to this metric, 
ArcPomc-KO mice showed a more exaggerated sensitization than did WT mice (Figure 2.7C).  
 
ArcPomc-KO mice have altered brain expression of melanocortin system but not dopamine 
system genes.   
 mRNA levels of a panel of hypothalamic genes previously shown to be involved in food 
intake, metabolism, and voluntary running wheel activity were measured in the mice from the 
running wheel experiment (Table 2.3). As expected, Pomc mRNA was very low in all ArcPomc-
KO mice with no difference between groups. In obese ArcPomc-KO mice of both sexes, mRNA 
levels of the anorexigenic peptide CART (cocaine and amphetamine-related transcript, Cartpt) 
were increased compared to WT. Likewise, mRNA levels of the orexigenic peptides 
neuropeptide Y (Npy) and agouti-related protein (Agrp) were decreased in obese ArcPomc-KO 
compared to WT. None of these genes was affected by access to a running wheel in either 
genotype. Weight-matched ArcPomc-KO mice had normalized levels of Cartpt but weight-
matching did not affect levels of Npy and Agrp. Hypocretin (Hcrt, also known as orexin) and 
brain-derived neurotrophic factor (Bdnf) levels have previously been shown to be affected by 
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voluntary exercise (109), but no differences were found between groups in this study. Similarly, 
there were no differences in Mc3r expression (Table 2.3). 
 The dopaminergic system has been highly implicated in spontaneous and voluntary 
locomotor activity as well as motivation and reward. We measured expression levels of genes 
involved in the dopaminergic system in a separate cohort of female mice. mRNA levels of 
tyrosine hydroxylase (Th), the rate-limiting enzyme in production of dopamine, dopamine 
receptors Drd1 and Drd2 as well as the dopamine transporter Slc6a3 were not different between 
genotypes in either the ventral tegmental area (VTA)/substantia nigra (SN) or the nucleus 
accumbens (NAcc) (Figure 2.8A). Because gene expression does not necessarily correlate with 
protein levels, immunohistochemistry was used to quantify immunoreactivity of TH protein in 
the VTA and SN pars compacta (SNc) (Figure 2.8B). In both structures, there was no difference 
in TH immunoreactivity between the genotypes (Figure 2.8C). 
 
Discussion 
  
 This study was designed to disentangle a primary role for ArcPomc in the regulation of 
spontaneous and voluntary locomotion from its effects on body weight via food intake. We 
found that obese ArcPomc-KO mice exhibited decreased spontaneous home cage activity levels 
which were normalized by weight-matching, suggesting that ArcPomc does not play a direct role 
in regulation of spontaneous locomotion. Rather, these data support the idea that obesity can lead 
secondarily to decreased spontaneous locomotion, although obese ArcPomc-KO mice are 
physically capable of high levels of activity, as evidenced from the morphine sensitization assay. 
On the other hand, both obese and weight-matched ArcPomc-KO mice showed less voluntary 
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running wheel activity than controls, suggesting that ArcPomc is directly involved in this 
motivated behavior. We also found that male ArcPomc-KO mice exhibited decreased food 
anticipatory activity (FAA).  
 ArcPOMC neurons receive and integrate peripheral signals related to energy status and 
could regulate locomotor activity in response to these signals. Specifically, catabolic POMC-
derived melanocortin peptides may be expected to upregulate activity levels in response to 
positive energy balance in order to expend more energy. Indeed, similar studies have uncovered 
a critical role for leptin, an adipocyte-derived hormone well-studied for its role in feeding 
behavior, in control of physical activity. Leptin-deficient ob/ob mice are obese and hyperphagic, 
and they exhibit markedly decreased spontaneous home cage locomotion (94,95). Acute leptin 
administration increased spontaneous locomotor activity in ob/ob mice before any noticeable 
change in body weight occurred (94,95), suggesting that the obesity and hypolocomotion seen in 
ob/ob mice are dissociable and that leptin can directly modulate spontaneous activity levels 
independently of its role in regulation of body weight. 
 Reactivation of leptin receptor (LepR) in only the Arc of mice otherwise lacking LepR 
dramatically improved the decreased spontaneous home cage locomotion of LepR-null mice, 
while only mildly reducing body weight, leading to the hypothesis that leptin regulates 
spontaneous locomotor activity via neurons in the Arc (96). Both POMC and AGRP neurons in 
the Arc are leptin-responsive. Mice that were engineered to lack LepR expression only in Agrp-
expressing neurons were mildly obese and showed less spontaneous locomotor activity than 
controls, whereas mice lacking Lepr only in Pomc neurons were also mildly obese but had 
normal locomotor activity levels (189). Additionally, mice with constitutively active Stat3, a 
transcription factor downstream of LepR, in Agrp neurons were lean and hyperlocomotive (99), 
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whereas constitutive activation of Stat3 in Pomc neurons led to mild obesity and insulin 
resistance but no change in activity levels (99,190). However, Agrp-KO mice exhibit normal 
levels of spontaneous home cage locomotion (29). Together these results suggest that leptin’s 
effect on spontaneous locomotion is mediated via Arc AGRP neurons rather than POMC neurons 
and may not be dependent on melanocortin signaling, and our data are in agreement with this 
conclusion. 
 Ob/ob mice also have decreased voluntary running wheel activity, which increases 
acutely after leptin administration (94,95,191). The mechanism by which leptin regulates 
voluntary running wheel activity has been less well-studied than its effects on spontaneous 
locomotor activity. Since both leptin and ArcPomc can modulate running wheel activity 
independently of obesity and ArcPomc is known to be activated by leptin, it is certainly possible 
that ArcPomc is downstream of leptin in one pathway controlling voluntary running wheel 
activity levels. ArcPOMC neurons also respond to other peripheral and central signals and could 
regulate voluntary activity independently of leptin. These questions deserve further investigation.   
 POMC is also cleaved into β-endorphin, which has been shown to be released into the 
bloodstream in humans (192,193) and into the cerebrospinal fluid in rats (194) during running, 
and some believe it may be involved in the cognitive and mood enhancements that are associated 
with exercise, although the mechanism is unknown. To test if the decreased voluntary running 
wheel activity that we observed in ArcPomc-KO mice was due specifically to lack of β-
endorphin, we repeated these experiments in a cohort of β-endorphin-KO mice, which have 
intact neural melanocortin signaling but are missing β-endorphin throughout the body (184). We 
hypothesized that if exercise activates reward circuitry via β-endorphin, mice lacking β-
endorphin would not exhibit the same level of voluntary running wheel activity as WT controls. 
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However, we found that β-endorphin-KO mice ran the same distance as WT mice throughout the 
course of the experiment, which is in agreement with another report using running wheels in the 
same strain of mice (195). These data, together with the findings that mice selectively bred for 
high voluntary running levels display equal analgesia to WT mice and respond the same as WT 
mice when administered opioid antagonists (196), and that mice injected daily with naloxone do 
not change their running behavior (197), suggests that the endogenous opioid system, or at least 
β-endorphin, does not play a role in determining levels of voluntary locomotion. Thus we 
postulate that the lack of running wheel activity in ArcPomc-KO mice described in this report is 
a direct result of lack of melanocortin signaling. 
 The dopaminergic system has been heavily implicated in control of locomotion and 
voluntary physical activity (for review, see (80,103)) in addition to motivation for other rewards. 
Dopaminergic neurons in the VTA receive both direct and indirect input from POMC neurons. 
However, using qPCR we found no difference between WT mice and obese ArcPomc-KO mice 
in the mRNA levels of Th or any dopamine receptor or its plasma membrane transporter in the 
midbrain as well as no difference in TH protein levels by semi-quantitative immunofluorescence. 
Additionally, mRNA levels of several dopamine receptors and the transporter were not different 
between genotypes in the NAcc, a key target nucleus for VTA dopaminergic nerve terminals that 
has been implicated in motivation and reward in addition to locomotor activity. These results do 
not preclude the possibility of the dopaminergic system being involved in the downstream effects 
of ArcPomc on locomotor activity, but indicate that chronic changes in gene transcription are not 
part of the mechanism. Rather, genotypic differences in the pattern or amount of dopamine 
release or receptor sensitivity could underlie the defect in voluntary locomotion observed in 
ArcPomc-KO mice. 
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  Both WT and ArcPomc-KO mice exhibited profound sex differences in spontaneous 
home cage and voluntary running wheel behavior. Our results agree with previous studies that 
found female WT mice exhibited higher activity levels than male WT mice. Weight-matching 
ArcPomc-KO mice rescued total daily spontaneous home cage activity, but not food anticipatory 
activity, to the same degree in mice of both sexes, whereas voluntary running wheel activity was 
more dramatically decreased in female than male ArcPomc-KO mice. Mechanisms underlying 
sex differences in activity levels is an understudied field, and most reports have not differentiated 
between spontaneous home cage locomotor activity and running wheel activity. Gonadectomy of 
either sex reduces locomotor activity levels, and replacement with either estrogen or testosterone 
rescues that effect, suggesting that both of these hormones can increase locomotion (198). One 
study implicated estrogen receptor (ER)-α as a mediator of the sex differences in running wheel 
behavior (199), and approximately 25-30% of ArcPOMC neurons express ER-α (40). Therefore, 
estrogen signaling in ArcPOMC neurons could be one mechanism by which gonadal hormones 
influence voluntary activity levels. Another possibility is that estrogen regulates voluntary wheel 
running behavior via actions at another site and that estrogen levels are decreased by ArcPomc 
ablation. Circulating levels of sex hormones in ArcPomc-KO mice have not been measured, but 
the uterine mass of the females is approximately half that of WT, suggesting an estrogen 
deficiency (unpublished observation).  
 Mice are known to exhibit food anticipatory activity (FAA) when food access is 
restricted to a certain time each day. There is extensive evidence that FAA does not rely on any 
known circadian clock but rather on some as-yet unidentified food entrainable oscillator (112). 
Whereas I have hypothesized above that spontaneous and voluntary activity may be upregulated 
when energy balance becomes positive, FAA is believed to reflect foraging behavior and occurs 
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when rodents are in a negative energy balance. Thus the mechanisms regulating 
spontaneous/voluntary activity and FAA are unlikely to be the same. Indeed, leptin is not 
necessary for FAA, as ob/ob mice actually exhibited increased FAA over WT mice (95). We 
have now shown that ArcPOMC is also not necessary for FAA, since it is intact in ArcPomc-KO 
mice. However, the amplitude of FAA is decreased specifically in male ArcPomc-KO mice. 
Another group studying male Mc3r-KO mice has observed a similar phenotype in those mice 
(87,88). Therefore, ArcPOMC acting via Mc3r may play a modulatory role in FAA specifically 
in males, but the physiological significance of this pathway is unclear. Interestingly, FAA 
comprises a greater percentage of total activity levels in male mice compared to female mice, an 
effect which is dependent on sex hormones (200). Hypothalamic Pomc expression in rats is 
positively regulated by testosterone (201). Based on these previous studies, the relatively lower 
level of FAA exhibited by male ArcPomc-KO in comparison to male WT mice could reflect an 
absence of this “boosting” effect of testosterone on FAA.  
 Ad libitum-fed ArcPomc-KO mice given access to a running wheel did not have a 
markedly improved metabolic phenotype. In females, none of the metabolic parameters 
measured were improved by access to a running wheel, whereas in males, fat mass and 
cholesterol were somewhat lowered. The study was designed to dissociate positive effects of 
exercise from those of normalized body weight, but the results are difficult to interpret because 
obese ArcPomc-KO mice did not exhibit high levels of voluntary running wheel activity. Weight 
matching ArcPomc-KO mice to WT mice by food restriction did restore plasma glucose, insulin 
and cholesterol levels to normal even without increasing activity levels, suggesting that reduction 
in body weight, and in particular fat mass, is the more important factor for promoting metabolic 
health.  
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 In order to identify potential downstream mediators of ArcPomc’s regulation of 
locomotion and metabolism, we used qPCR to measure hypothalamic mRNA levels of a panel of 
candidate genes in the mice from the running wheel study. The anorexigenic peptide Cartpt was 
upregulated in obese ArcPomc-KO mice but normalized after weight-matching, suggesting its 
upregulation to be a compensatory effect secondary to obesity. The orexigenic peptides Agrp and 
Npy were downregulated in obese ArcPomc-KO mice but, with the exception of Agrp in males, 
were not normalized by weight-matching. This suggests that ArcPOMC may directly stimulate 
expression of Agrp and/or Npy in the hypothalamus independent of body weight. Another 
explanation is that, although weight-matched ArcPomc-KO mice weighed the same as WT mice, 
they still had elevated fat mass and were hyperleptinemic (data not shown), and enhanced leptin 
signaling to AGRP/NPY neurons could inhibit transcription of those genes. Previously identified 
putative mediators of physical activity levels include Bdnf and Hcrt (94), but we found no 
change in the mRNA levels of these genes in any group studied.  
 In summary, ArcPomc affects locomotor activity in two distinct ways. ArcPomc-KO 
mice developed hyperphagic obesity, and as a consequence exhibited decreased levels of 
spontaneous home cage locomotor activity levels. Thus obesity in ArcPomc-deficiency, while 
primarily caused by altered food intake, could be exacerbated by decreased spontaneous activity.  
ArcPomc is not necessary for spontaneous locomotion, as locomotor activity levels of ArcPomc-
KO mice were normalized by weight-matching. However, ArcPomc plays a modulatory role in 
the degree of voluntary running wheel independently of body weight, and ArcPomc-deficiency 
could additionally contribute to obesity via decreased motivated exercise behavior.  
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Table 2.1: Primers used for semi-quantitative RT-PCR in the hypothalamus, midbrain 
and ventral striatum. 
Gene 
Symbol Gene Name 
Forward Primer, 
5’-3’ 
Reverse Primer,  
5’-3’ 
Agrp Agouti-related neuropeptide TGTGTTCTGCTG
TTGGCACT 
GCTCGGTCTGCA
GTTGTCTT 
Bdnf Brain-derived neurotrophic 
factor 
TTGTTTTGTGCC
GTTTACCA 
TGTGATGGGGAT
CCTTTTGT 
Cartpt Cocaine and amphetamine-
regulated transcript 
prepropeptide 
CGAGAAGAAGT
ACGGCCAAG 
GTCGTCCCTTCA
CAAGCACT 
Drd1 Dopamine receptor D1 GAGCGTGGTCTC
CCAGAT 
GTCCCTAGATTC
CCCAAGGA 
Drd2 Dopamine receptor D2 AAGCGCCGAGTT
ACTGTCAT 
GGCACGTAGAAC
GAGACGAT 
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
GGTGCTGAGTAT
GTCGTGGA 
GTGGTTCACACC
CATCACAA 
Hcrt Hypocretin (Orexin) CTCCAGGCACCA
TGAACTTT 
AGTTCGTAGAGA
CGGCAGGA 
Mc3r Melanocortin 3 receptor AGGAAAGCCCTC
ACCTTGAT 
GCGAAGAGGAA
CATGTGGAT 
Npy Neuropeptide Y GTGTGTTTGGGC
ATTCTGG 
TGTCTCAGGGCT
GGATCTCT 
Pomc Proopiomelanocortin GAGCTGGTGCCT
GGAGAG 
TTTTCAGTCAGG
GGCTGTTC 
Ppia Peptidylprolyl isomerase A 
(Cyclophilin A) 
CACCGTGTTCTT
CGACATCA 
CAGTGCTCAGAG
CTCGAAAGT 
Slc6a3 Solute carrier family 6, member 
3 (Dopamine transporter) 
AACCTGTACTGG
CGGCTATG 
ATGGAGGATGTG
GCAATGAT 
Th Tyrosine hydroxylase TGAAGCCAAAAT
CCACCACT 
TGACACTTTCCT
TGGGAACC 
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Table 2.2: Metabolic parameters after running wheel access in obese and weight-matched 
ArcPomc-KO mice. 
 
 
 Without Wheel With Wheel One-way 
ANOVA 
 
F(4,20) = A. Male 
WT ArcPomc-KO WT 
ArcPomc-
KO 
WM 
ArcPomc-
KO 
Body Weight, g 22.1 ± 0.9  
43.8 ± 0.9 
*** 
22.9 ± 0.5 36.8 ± 2.2 
***, ††† 
22.1 ± 0.3 
††† 
83.2 
P < 0.001 
Food Intake, g 4.0 ± 0.2 5.9 ± 0.2 *** 
3.9 ± 0.1 5.4 ± 0.2 
*** 
3.7 ± 0.1 
††† 
25.6 
P < 0.001 
Lean Mass, g 17.4 ± 0.8 23.0 ± 0.5 *** 
17.8 ± 0.4 21.1 ± 0.7 
*** 
15.8 ± 0.3 
††† 
24.7 
P < 0.001 
Lean Mass, % 76.3 ± 0.7 49.3 ± 0.3 *** 
76.6 ± 0.9 52.7 ± 0.8 
***, † 
65.9 ± 1.1 
***, ††† 
253.1 
P < 0.001 
Fat Mass, g 1.5 ± 0.1 17.5 ± 0.3 *** 
1.3 ± 0.1 13.5 ± 0.9 
***, ††† 
4.6 ± 0.4 
***, ††† 
238.5 
P < 0.001 
Fat Mass, % 6.5 ± 0.5 37.6 ± 0.5 *** 
5.7 ± 0.5 33.6 ± 1.0 
***, †† 
19.2 ± 1.3 
***, ††† 
322.1 
P < 0.001 
Fasting blood 
glucose, mg/dL 
89.4 ± 10.9 133.0 ± 9.2 
** 
89.8 ± 9.5 122.6 ± 
11.5 
80.8 ± 3.3 
†† 
6.4 
P < 0.01 
GTT AUC, 
mg*hr/dL 
25584 ± 
1898 
44393 ± 
6781 
31223 ± 
6166 
42559 ± 
7238 
31161 ± 
2224 
2.2 
n.s. 
Fasting plasma 
insulin, ng/mL 
0.44 ± 0.10 3.63 ± 0.31 
** 
0.52 ± 0.10 3.03 ± 1.00 
* 
1.46 ± 0.71 
† 
7.2 
P < 0.001 
Cholesterol, 
mg/dL 
61.8 ± 5.2 91.0 ± 4.0 
*** 
61.0 ± 2.1 73.2 ± 7.1 
† 
56.0 ± 2.2 
††† 
10.5 
P <  0.001 
B. Female       
Body Weight, g 19.0 ± 0.3  
39.4 ± 0.4 
*** 
19.4 ± 0.4 35.3 ± 2.3 
*** 
20.3 ± 0.4 
††† 
80.9 
P < 0.001 
Food Intake, g 4.4 ± 0.3 5.9 ± 0.2 *** 
4.1 ± 0.2 5.2 ± 0.2 3.2 ± 0.1  
**, ††† 
26.0 
P < 0.001 
Lean Mass, g 14.8 ± 0.4 20.7 ± 0.5 *** 
14.9 ± 0.4 18.2 ± 0.9 
**, † 
13.1 ± 0.2 
††† 
30.3 
P < 0.001 
Lean Mass, % 76.1 ± 1.1 48.8 ± 0.5 *** 
75.5 ± 0.5 47.1 ± 0.7 
*** 
60.5 ± 0.9 
***, ††† 
300.1 
P < 0.001 
Fat Mass, g 1.4 ± 0.2 16.7 ± 0.7 *** 
1.4 ± 0.1 15.6 ± 1.1 
*** 
5.3 ± 0.3 
***, ††† 
154.4 
P < 0.001 
Fat Mass, % 7.4 ± 1.2 39.3 ± 0.7 *** 
7.2 ± 0.4 40.3 ± 0.6 
*** 
24.6 ± 0.9 
***, ††† 
395.7 
P < 0.001 
Fasting blood 
glucose, mg/dL 
86.4 ± 6.0 109.0 ± 
11.3 
80.4 ± 3.6 123.4 ± 7.4 
** 
77.4 ± 4.3 
†† 
8.7 
P < 0.001 
GTT AUC, 
mg*hr/dL 
24,882 ± 
4,714 
55,413 ± 
9,747 ** 
24,927 ± 
2,933 
41,604 ± 
5,377 
30,845 ± 
1,233 †† 
6.0 
P < 0.01 
Fasting plasma 
insulin, ng/mL 
0.51 ± 0.24 2.08 ± 0.50 0.60 ± 0.11 3.57 ± 0.87 
*** 
0.69 ± 0.17 8.8 
P < 0.001 
Cholesterol, 
mg/dL 
46.6 ± 3.9 88.4 ± 3.3 
*** 
48.4 ± 1.7 83.8 ± 3.3 
*** 
43.3 ± 2.8 
††† 
49.7 
P < 0.001 
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Measurements in 12-15 week old male (A) and female (B) WT and obese ArcPomc-KO mice 
with or without a wheel and weight-matched ArcPomc-KO with a wheel are shown. Data are 
mean ± SEM and were analyzed by one-way ANOVA between groups (n.s.: not significant). N = 5 per 
sex and group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to WT without a wheel; † P < 0.05, †† P 
< 0.01, ††† P < 0.001 compared to obese ArcPomc-KO without a wheel by Dunnett’s post hoc multiple 
comparison tests.   
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Table 2.3: Hypothalamic gene expression levels after access to a running wheel in obese 
and weight-matched ArcPomc-KO mice. 
 
 Without Wheel With Wheel One-way 
ANOVA 
 
F(4,20) = A. Male 
WT ArcPomc-KO WT 
ArcPomc-
KO 
WM 
ArcPomc-
KO 
Pomc 100 ± 14 8 ± 2  
*** 
99 ± 8 7 ± 1  
*** 
6 ± 1  
*** 
50.1 
P < 0.001 
Cart 100 ± 4 164 ± 9 
*** 
98 ± 5 136 ± 12  
* 
101 ± 12 
††† 
11.0 
P < 0.001 
Npy 100 ± 12 49 ± 1  
*** 
87 ± 11 50 ± 1  
*** 
59 ± 3  
** 
12.2 
P < 0.001 
Agrp 100 ± 15 50 ± 3  
*** 
81 ± 7 59 ± 4  
** 
77 ± 8 6.0 
P < 0.01 
Mc3r 100 ± 1 93 ± 4 84 ± 3 92 ± 6 94 ± 5 1.7 
n.s. 
Hcrt 100 ± 6 86 ± 3 90 ± 6 84 ± 6 93 ± 10 1.0 
n.s. 
Bdnf 100 ± 4 104 ± 3 105 ± 5 95 ± 7 94 ± 2 1.2 
n.s. 
B. Female       
Pomc 100 ± 11 3 ± 0  
*** 
120 ± 23 4 ± 1  
*** 
2 ± 0  
*** 
31.9 
P < 0.001 
Cart 100 ± 12 133 ± 8 84 ± 5 136 ± 7 80 ± 13  
†† 
6.7 
P < 0.01 
Npy 100 ± 13 43 ± 3  
** 
77 ± 8 43 ± 3  
** 
47 ± 10  
** 
7.7 
P < 0.001 
Agrp 100 ± 9 36 ± 2  
*** 
106 ± 14 39 ± 6  
*** 
37 ± 10 
*** 
14.6 
P < 0.001 
Mc3r 100 ± 10 110 ± 8 86 ± 11 102 ± 10 95 ± 20 0.4 
n.s. 
Hcrt 100 ± 8 75 ± 9 97 ± 11 74 ± 3 69 ± 12 2.1 
n.s. 
Bdnf 100 ± 10 86 ± 6 95 ± 15 89 ± 6 105 ± 29 0.2 
n.s. 
 
 
Hypothalamic mRNA levels of genes associated with energy homeostasis and locomotor activity 
were assayed by semi-quantitative real-time PCR, normalized to Gapdh, and expressed as a 
percentage of WT without a wheel. Data from male (A) and female (B) WT and obese ArcPomc-
KO mice with or without a wheel and weight-matched ArcPomc-KO with a wheel are shown. 
Data are mean ± SEM and were analyzed by one-way ANOVA between groups (n.s.: not significant). N 
= 5 per sex and group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to WT without a wheel; †† P < 
0.01, ††† P < 0.001 compared to obese ArcPomc-KO without a wheel by Dunnett’s post hoc multiple 
comparison tests.   
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Figure 2.1: Spontaneous home cage locomotor activity levels in obese and weight-
matched ArcPomc-KO mice. In both panels, male (left) and female (right) data are shown. A, 
Body weight of 20-week old WT and ArcPomc-KO mice fed ad libitum and following 10 
weeks of food restriction. RMANOVA showed a significant effect of genotype (Male, F(1,14) 
= 403.1; Female, F(1,14) = 264.5), nutrition status (Male, F(1,14) = 504.1; Female, F(1,14) = 
361.5), and an interaction (Male, F(1,14) = 208.2; Female, F(1,14) = 183.6). B, 24-hour spon-
taneous home cage horizontal locomotion distance of ad libitum-fed and food restricted WT 
and ArcPomc-KO mice. RMANOVA in males showed a significant effect of genotype (F(1,14) 
= 7.1) and nutrition status (F(1,14) = 29.8) but no interaction, whereas in females there was a 
significant effect of genotype (F(1,14) = 8.1), nutrition status (F(1,14) = 9.3), and an interac-
tion (F(1,14) = 11.4). N = 8 per sex and genotype. *** P < 0.001 by Sidak’s post-hoc multiple 
comparisons tests. Post hoc test results are not shown in panel A for clarity but each compari-
son was significant, P < 0.001, except between ad lib WT and WM ArcPomc-KO, which were 
not different from each other in either sex.
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Figure 2.2: Diurnal distribution of spontaneous home cage locomotor activity in obese 
and weight-matched ArcPomc-KO mice. In both panels, male (left) and female (right) data 
are shown. A, Night-time spontaneous home cage horizontal locomotion distance of ad 
libitum-fed and food restricted WT and ArcPomc-KO mice. In both sexes, RMANOVA 
showed a significant effect of genotype (Males, F(1,14) = 5.2; Females, F(1,14) = 15.5) and an 
interaction between genotype and nutrition status (Males, F(1,14) = 18.7; Females, F(1,14) = 
24.1). B, Day-time spontaneous home cage horizontal locomotion distance of ad libitum-fed 
and food restricted WT and ArcPomc-KO mice. In males, RMANOVA revealed a significant 
effect of genotype (F(1,14) = 6.6), nutrition status (F(1,14) = 65.6), and an interaction (F(1,14) 
= 9.4), whereas in females there was only a significant effect of nutrition status (F(1,14) = 
66.4). N = 8 per sex and genotype. * P < 0.05, ** P < 0.01, *** P < 0.001 by Sidak’s post-hoc 
multiple comparisons test.
0.0
0.5
1.0
1.5
2.0
Genotype, P < 0.05
Interaction, P < 0.001
0.0
0.5
1.0
1.5
2.0
Genotype, P < 0.01
Interaction, P < 0.001
0.0
0.5
1.0
1.5
2.0
Genotype, P < 0.05
Nutrition status, P < 0.001
Interaction, P < 0.01
0.0
0.5
1.0
1.5
2.0
Nutrition status, P < 0.001
D
is
ta
nc
e 
in
N
ig
ht
 (k
m
)
D
is
ta
nc
e 
in
D
ay
 (k
m
)
Ad Libitum Food Restricted Ad Libitum Food Restricted
Ad Libitum Food Restricted Ad Libitum Food Restricted
***
**
* ***
**
*
***
***
**
58
WT, ad lib ArcPomc-KO, ad lib
WT, calorie restricted ArcPomc-KO, WM
A
B
Male Female
Figure 2.3: Hourly bins of spontaneous home cage locomotor activity in obese and 
weight-matched ArcPomc-KO mice. In both panels, male (left) and female (right) data are 
shown and the gray box represents the dark cycle. A, Spontaneous home cage horizontal 
lcoomotor activity of ad-libitum fed WT and obese ArcPomc-KO mice in 1-hour bins over 23 
hours. B, Spontaneous home cage horizontal locomotor activity of food-restricted WT and 
weight-matched ArcPomc-KO mice in 1-hour bins over 23 hours. Arrows mark the time when 
the daily food allotment was administered. N = 8 per sex and genotype.
0
50
100
150
200
250
300
0
50
100
150
200
250
300
0
50
100
150
200
250
300
0
50
100
150
200
250
300
18:0
0
22:0
0 2:00 6:00 10:0
0
14:0
0
18:0
0
22:0
0 2:00 6:00 10:0
0
14:0
0
18:0
0
22:0
0 2:00 6:00 10:0
0
14:0
0
18:0
0
22:0
0 2:00 6:00 10:0
0
14:0
0
D
is
ta
nc
e 
pe
r 
ho
ur
 (m
)
D
is
ta
nc
e 
pe
r 
ho
ur
 (m
)
59
AB
Male Female
Figure 2.4: Body weight and voluntary running wheel activity in obese and weight-
matched ArcPomc-KO mice. In both panels, male (left) and female (right) data are shown. A, 
Body weight measured weekly from age 4-12 weeks in WT and ArcPomc-KO mice with or 
without a wheel as well as weight-matched (WM) ArcPomc-KO with a wheel. In both sexes, 
RMANOVA showed a significant effect of time (Males, F(8,168) = 617.0; Females, F(8,176) 
= 594.4), group (Males, F(4,21) = 64.7; Females, F(4,22) = 66.8), and an interaction (Males, 
F(32,168) = 55.7; Females, F(32,176) = 55.0). B, 24-hour running wheel activity in WT, obese 
and WM ArcPomc-KO measured weekly from age 5-11 weeks. In both sexes, RMANOVA 
showed a significant effect of time (Males, F(6,72) = 10.4; Females, F(6,84) = 2.8), group 
(Males, F(2,12) = 4.1; Females, F(2,14) = 14.2), and an interaction (Males, F(12,72) = 4.4;  
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Females, F(12,84) = 6.4). N = 5-7 per sex and group. * P < 0.05, ** P < 0.01, *** P < 0.001 
compared to WT without a wheel (Panel A) or WT with a wheel (Panel B); ††† P < 0.001 com-
pared to obese ArcPomc-KO without a wheel. Symbols indicate a main difference between 
groups by Dunnett’s post hoc multiple comparisons tests. 
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Figure 2.5: Diurnal distribution of voluntary running wheel activity in obese and 
weight-matched ArcPomc-KO mice. In both panels, male (left) and female (right) data are 
shown. A, Running wheel activity of WT, obese and WM ArcPomc-KO mice at 5 weeks old 
divided into the 12-hr dark and 12-hr light periods. RMANOVA in both sexes showed a signifi-
cant effect only of time of day (Male: F(1,12) = 55.2; Female: F(1,14) = 77.2). B, Running 
wheel activity of WT, obese and WM ArcPomc-KO mice at 11 weeks old divided into the 
12-hr dark and 12-hr light periods. RMANOVA in both sexes showed a significant effect of 
time of day (Male: F(1,12) = 97.3; Female: F(1,14) = 65.4), group (Male: F(2,12) = 13.5; 
Female: F(2,14) = 23.3), and an interaction (Male: F(2,12) = 15.0; Female: F(2,14) = 23.5). N 
= 5-7 per sex and group. * P < 0.05, *** P < 0.001 by Sidak’s post hoc multiple comparisons 
tests.  
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Figure 2.6: Voluntary wheel running activity levels of β-endorphin-KO mice.  Male (left) 
and female (right) data are shown. A, 24-hour running wheel activity in WT and β-endorphin-
KO mice mouse weekly from age 5-11 weeks. In both sexes, RMANOVA showed a significant 
effect of time (Males, F(6,77) = 5.0; Females, F(6,72) = 11.8) but not genotype. B, Running wheel 
activity of WT and β-endorphin-KO mice at 11 weeks old divided into the 12-hr dark and 12-hr 
light periods. RMANOVA in both sexes showed a significant effect of time of day (Males, F(1,22) 
= 102.8; Females, F(1,24) = 130.2) but not genotype. N = 6-7 per sex and genotype.
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Figure 2.7: Locomotor sensitization to morphine in obese ArcPomc-KO mice. For this 
study, the sexes were combined. A, Distance traveled in one hour by WT and ArcPomc-KO 
mice in both the saline control and experimental morphine groups on each day of the study. B, 
Distance traveled by each mouse on Day 0 for one hour immediately following i.p. injection 
of saline. The open versus closed circles indicate the group each mouse was assigned to for the 
following day of the test. Two-way ANOVA showed no effect of future drug group (saline or 
morphine) but a significant effect of genotype (F(1,44) = 29.3). C, Distance traveled by the 
morphine-administered groups on Day 1 and Day 8 (Panel A) were normalized to the genotype 
average from Day 0 (Panel B) and expressed as fold change to represent the sensitization 
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effect. RMANOVA showed a significant effect of genotype (F(1,22) = 33.5), day (F(1,22) = 
8.8), and an interaction (F(1,22) = 10.6). N = 12 per genotype and treatment. *** P < 0.001 by 
Sidak’s post hoc multiple comparisons tests. 
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Figure 2.8: mRNA and protein levels of the dopaminergic system in female ArcPomc-KO 
mice. A, mRNA levels of genes in the dopaminergic system were assayed by semi-quantitative 
real-time PCR, normalized to Gapdh (VTA/SN) or Ppia (NAcc) and expressed as a percentage 
of WT. B, Representative images from Bregma -3.08 mm of TH immunoreactivity in the VTA 
and SNc of each genotype are shown. C, Intensity of TH immunostaining in coronal sections 
120 μm apart throughout the length of the VTA and SNc was measured and summed in each 
mouse, and group averages are shown. N = 8 per genotype (Panel A) or 6 per genotype (Panel 
C). Data were analyzed with unpaired Student’s t-test between genotypes but no significant 
differences were found.
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Chapter 3: Arcuate-Specific Proopiomelanocortin-Deficiency Activates the 
Hypothalamic-Pituitary-Adrenal Axis Independently of Vasopressin 1B 
Receptor† 
 
Proopiomelanocortin (POMC) and its bioactive peptides are produced in anterior pituitary 
corticotroph cells, and peripheral release of these peptides plays a major role in the 
hypothalamic-pituitary-adrenal (HPA) stress axis. In the absence of pituitary-derived POMC 
peptides, the HPA axis does not develop at all. The other primary group of POMC-peptide 
producing cells is a subset of neurons in the arcuate nucleus of the hypothalamus (Arc), which 
may also play a role in regulating the HPA axis. In this study, we have made use of a recently-
developed genetic mouse model that does not express Pomc specifically in the hypothalamus but 
expresses Pomc at normal levels in the pituitary (ArcPomc-KO mouse). We have found that 
ArcPomc-KO mice have a hyperactive HPA axis, as indicated by adrenocortical hypertrophy and 
elevated circulating plasma stress hormones, in association with increased expression of critical 
HPA genes in the hypothalamus and pituitary. We identified hypothalamic arginine vasopressin 
(AVP) acting via AVP receptor 1b (V1bR) in the pituitary as a likely modulator of the HPA axis 
downstream of ArcPomc. Surprisingly, crossing ArcPomc-KO with Avpr1b-KO mice did not 
rescue the dysregulated HPA axis of ArcPomc-KO mice. Based on these results, we conclude 
that ArcPOMC tonically inhibits the HPA axis, opposite to the stimulatory actions of pituitary 
POMC. Consequently, reduced Pomc expression in the hypothalamus mediates the central 
dysregulation of the HPA axis independently of V1br-mediated AVP signaling.  
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_______________________ 
 
† Courtney Attard prepared, processed and analyzed the data presented in Figure 3.5C,D. Mouse 
colony maintenance and genotyping were performed by Jared Goldberg, Courtney Attard, and 
Eva Yokosawa. Avpr1b-KO mouse line kindly provided by Drs. Kazuaki Nakamura and Akito 
Tanoue. 
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Introduction 
 
Proopiomelanocortin (POMC) is a propeptide produced mainly in the arcuate nucleus of 
the hypothalamus (Arc) and the anterior lobe of the pituitary. POMC peptides released from 
~3000 neurons in the Arc play a critical role in the control of food intake and energy 
expenditure, whereas POMC peptides produced by corticotrophs in the anterior pituitary are 
mainly involved in activation of the hypothalamic-pituitary-adrenal (HPA) stress axis (7,13,202). 
Two strains of mice with a global deficiency in the POMC propeptide due to genetic mutation in 
the Pomc gene (Pomc-knockout (KO)) have been generated by separate laboratories (23,24). 
Both strains are hyperphagic and obese due to loss of anorexigenic and catabolic peptide 
signaling in the central nervous system (CNS). Furthermore, the adrenal glands do not develop 
properly postnatally secondarily to the absence of circulating adrenocorticotrophic hormone 
(ACTH). Therefore, Pomc-KO mice have no measurable circulating glucocorticoids (GCs) either 
basally or upon stimulation by a stressor (4,179). 
The predominant GC in rodents is corticosterone, which is a critical regulator of the 
body’s response to stress. Corticosterone is the final effector molecule in the HPA stress axis, 
and GC dysregulation can profoundly impact the immune, cardiovascular, reproductive and 
metabolic systems. In an effort to separate the primary metabolic role of Pomc in the CNS from 
secondary effects caused by lack of corticosterone, we previously crossed Pomc-KO mice with a 
mouse engineered to carry a transgene directing Pomc expression only to pituitary cells but not 
to neurons, effectively creating a neuron-specific Pomc-KO (181). We found that genetic 
restoration of corticosterone to Pomc-KO mice exacerbated their metabolic phenotype, mostly 
through increased fat accretion, in agreement with another group that restored corticosterone to 
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Pomc-KO mice via the drinking water (145,181). We predicted that expression of the pituitary-
specific Pomc-expressing transgene would completely normalize corticosterone in Pomc-KO 
mice, and indeed we found that the diurnal rhythm of corticosterone as well as the rise in 
corticosterone in response to a stressor were preserved. Surprisingly, specifically in male neuron-
specific Pomc-KO mice, plasma corticosterone levels were significantly elevated over WT 
controls (181,182), suggesting a direct role for hypothalamic Pomc in inhibition of the HPA axis. 
However, presence of the Pomc-null allele, but not the transgene, was associated with 
development of late-onset pituitary adenomas, predoimenantly arising from intermediate lobe 
melanotrophs, complicating our interpretations of these results (182). 
The production and release of ACTH in corticotrophs is controlled by corticotropin-
releasing hormone (CRH) and arginine vasopressin (AVP), both of which are released into the 
median eminence by cells in the paraventricular nucleus of the hypothalamus (PVH). The PVH 
receives and integrates synaptic and peptidergic inputs from across the CNS, including the 
brainstem, amygdala, hippocampus and other hypothalamic nuclei, but many of these 
connections have not been fully characterized. ArcPOMC neurons project directly to the PVH 
and to several candidate relay nuclei such as the amygdala, but a consensus on the role of Arc 
POMC neurons in regulation of the HPA axis has not been reached. 
Opioids are known to have an inhibitory role on the HPA axis, and β-endorphin is one of 
the cleavage products of the POMC propeptide (183). However, the HPA axis of β-endorphin-
KO mice was completely normal (184), suggesting that the specific lack of neuronal β-endorphin 
did not cause the observed increase in the HPA axis of neuron-specific Pomc-KO mice. The 
other major cleavage products of POMC in the Arc, including α-melanocyte stimulating 
hormone (MSH) and γ-MSH, are known as the melanocortins. Pharmacological manipulations in 
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rats have suggested an acute stimulatory rather than inhibitory role for central melanocortins on 
the HPA axis. Injection of α-MSH or the synthetic melanocortin receptor agonist melanotan II 
into either the cerebral ventricles or the PVH increased circulating corticosterone for up to thirty 
minutes (168,170,171,174). Physiologically, Pomc is expressed at a relatively constant, high 
level and is believed to be involved in setting a tonic signal in the brain. Implantation of an 
ACTH-containing pellet into the median eminence of rats for one week decreased corticosterone 
(161), suggesting that the melanocortins may affect the HPA axis differently on different time 
scales. Moreover, there may be a species difference in the actions of the melanocortins on the 
HPA axis, and similar experiments have not been reported in mice. 
In this study, we have found that a newly-developed ArcPomc-KO mouse model, which 
does not develop pituitary tumors, exhibits the same HPA phenotype as we reported previously 
in the neuron-specific Pomc-KO mouse model, confirming a role for neuronal Pomc in the 
regulation of the HPA axis. We then extensively characterized the HPA axis of ArcPomc-KO 
mice and identified hypothalamic arginine vasopressin (AVP) as a possible downstream effector 
for arcuate POMC. To test the role of AVP in the dysregulated HPA axis of ArcPomc-KO mice, 
we crossed these mice with mice lacking vasopressin receptor 1b (V1bR), the receptor expressed 
in the anterior pituitary by which AVP regulates release of ACTH, and characterized the HPA 
axis of the double-knockout (DKO) mice. Unexpectedly, the DKO did not rescue the HPA 
phenotype of the ArcPomc-KO mice, indicating that arcuate POMC inhibits the HPA axis 
independently of AVP signaling via V1bR. 
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Materials and Methods 
 
Animals. All mouse strains were backcrossed onto the C57Bl/6J background for at least 
ten generations. ArcPomc-KO mice, also called fneoΔ1Δ2, have been described previously and 
are phenotypically indistinguishable from a similar reactivatable ArcPomc-KO mouse in the 
absence of rescue (86,186). KO and wildtype (WT) littermates were generated by breeding 
ArcPomc heterozygotes. Avpr1b-KO mice were kindly provided by Dr. Akito Tanoue (203). 
Heterozygotes were crossed with ArcPomc-heterozygotes to create the experimental 
ArcPomc:Avpr1b-DKO group as well as three control groups: ArcPomc-KO, Avpr1b-KO and 
WT.  Ad libitum fed mice (standard chow) were housed in groups of 2-5 of mixed genotypes in 
ventilated cages at 72 ± 2°F with lights on 6:00 am to 6:00 pm and free access to water. For 
calorie restriction, 20-week old mice were singly-housed and given enough food daily at 10:00 
am to obtain and maintain the desired body weight. WT mice were restricted to 85% of their 
starting body weight and ArcPomc-KO mice were restricted to the average of the starting weight 
of the WT group for each sex. Animal studies were approved by the University Committee for 
Use and Care of Animals at the University of Michigan and followed the Public Health Service 
guidelines. 
 
Stress-free plasma collection. Whole blood for unstressed corticosterone analysis was 
collected from pair-housed mice via tail nick within 2 minutes of cage disturbance from one 
mouse per cage per day. Samples were collected at ages 4, 6 and 8 weeks at 9:00 am and at 5:00 
pm at least two days apart. Morning and evening samples from the same age were always from 
the same mouse whereas some mice were also used at multiple ages (n=9-10 per sex, genotype 
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and age). For analysis of plasma at age 2 weeks, all pups in a litter were decapitated at 5:00 pm, 
trunk blood collected into heparinized capillary tubes, and a tail sample taken to determine 
genotype (n=10 per sex and genotype). For the longitudinal study in Figure 3.9, samples were 
collected at 5:00 pm from the same mice (n=6-8 per sex and genotype) at each age. Blood 
samples were centrifuged for 10 min at 2,000 rpm and plasma was stored at -20°C prior to 
hormone analysis.   
 
Restraint stress. All restraint stress experiments were performed for 20 minutes on pair-
housed mice between 9:00 am and 10:00 am. For ArcPomc-KO mice and controls at age 8 weeks 
(n=6-8 per sex and genotype) and ArcPomc:Avpr1b-DKO mice and controls at age 16 weeks (n 
= 6-8 per sex and genotype), a basal blood sample was obtained from both mice in each cage for 
analysis of basal corticosterone within 2 minutes of cage disturbance. Lean mice were coaxed 
into a 50-mL conical tube modified with breathing holes whereas obese mice were coaxed into a 
modified rat restraint device (BrainTree Scientific). For restraint stress of ArcPomc-KO mice 
and controls at age 4-6 months (n = 5-6 per sex and genotype), a baseline morning plasma 
sample was collected from one mouse per cage per day. One week later, mice were subjected to 
restraint as described. For all experiments, mice in the restraint devices were placed back into the 
home cages for 20 minutes, then immediately removed and euthanized by decapitation. To 
measure basal ACTH in ArcPomc-KO mice, a separate cohort of pair-housed 8-week old mice 
(n=7-8 per sex and genotype) and of group-housed 16-week old mice (n = 3-9 per sex and 
genotype) were euthanized by decapitation at 9:00 am. Trunk blood was collected into a 
microcentrifuge tube containing 10 µL of 75 mg/ml EDTA, centrifuged at 3,500 rpm, and 
aliquots of plasma were stored at either -20°C (corticosterone) or -80°C (ACTH) prior to assay.  
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 Hormone analysis. Plasma samples were analyzed for corticosterone by enzyme 
immunoassay (EIA, Arbor Assays) or for ACTH by enzyme-linked immunosorbent assay 
(ELISA, MD Bioproducts) or immunoradiometric assay (IRMA, DiaSorin). For the 
corticosterone assay, plasma was diluted 1:100 in assay buffer, assayed in singlet, and 
concentration was determined based on the optical density of the standard curve using a four-
parameter logistic fit in Prism 6.0 (GraphPad). Sample values below the lowest value on the 
standard curve (7.8 ng/mL) were assigned that value. For both ACTH assays, 200 µL plasma 
was required. Individual samples containing less than 200 µL plasma were diluted up to 1:4 in 
assay buffer, assayed in singlet, and concentration was determined as above, although the 
readout from the IRMA was cpm as determined by gamma counter. All plasma samples from 8-
week old mice were analyzed by ELISA and all samples from 4-6 month old mice were analyzed 
by IRMA. Sample values below the lowest value on the standard curve (6.2 pg/mL, EIA; 9.9 
pg/mL, IRMA) were assigned that value. 
 
Behavioral tests. Two cohorts of mice were administered a battery of 3-4 consecutive 
tests separated by approximately one week. For young, pre-obese mice, the first test was 
performed at age 4 weeks and the last at age 8 weeks (n = 6-9 per sex and genotype). The older, 
obese mice were tested between 12 and 15 weeks of age (n = 5-9 per sex and genotype). For all 
tests, mice were housed in the adjoining room from the testing room and were brought into the 
testing room to acclimate for at least 30 minutes, and tests were performed between 9:00 am and 
12:00 pm. The open field test was performed first. For three consecutive days, mice were gently 
placed into a 41 x 41 cm box and their movement was tracked using infrared beams. On the third 
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day, the total distance moved and the percentage of time each mouse spent in the center of the 
field was calculated using Activity Monitor software (MedPC). For the elevated plus maze test, 
each mouse was placed into the center of the maze facing a closed arm. Each arm of the maze 
measured 30 x 5 cm with a 5 x 5 cm center block between the arms. Movement was recorded by 
video camera for 5 minutes. The videos were later analyzed for time spent in the closed arms, 
open arms, or center of the maze. For the forced swim, mice were gently placed into a beaker 
with diameter 15 cm of room temperature water and their behavior recorded for 6 minutes by 
video camera. The last 4 minutes of each video was scored for swimming/struggling/climbing or 
floating behavior. For the novelty-suppressed feeding test, mice were fasted overnight and then 
placed into a large open field (different from the one mentioned above, but also 41 x 41 cm) with 
a small piece of regular rodent chow at the center and video recorded for 10 minutes. The videos 
were analyzed for time to approach food and time to eat food. Following the test, each mouse 
was returned to the home cage and its behavior monitored for 5 minutes. 
 
Semi-quantitative real-time PCR. Singly-housed 5-6 month old males (n=8 per genotype) 
were euthanized at 5:00 pm by decapitation and both adrenal glands were collected and stored at 
-80°C. At age 8 or 16 weeks, pair-housed mice (n = 7-8 per age, sex and genotype) were 
euthanized by decapitation at 9:00 am, and the hypothalamus and anterior pituitary were 
dissected and stored at -80°C. Total nucleic acid from each tissue was extracted using RNeasy 
spin columns (Qiagen) and DNA was removed via Turbo DNase treatment (Life Technologies). 
Total RNA was quantified and quality-checked via NanoDrop (ThermoScientific). Reverse 
transcription was performed to produce cDNA from 180 (anterior pituitary) or 500 
(hypothalamus, adrenal) ng total RNA using random hexamer primers (Goscript RT System, 
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Promega). Real-time PCR was performed on all samples in duplicate using the StepOne Real 
Time PCR System (Applied Biosystems) and SYBR Green Master Mix (Life Technologies). 
Primers listed in Table 3.1 were designed using Primer3 (187) to span at least one intron, when 
possible, and were used at a final concentration of 300 nM. The relative quantity of mRNA in the 
samples was calculated from a standard curve spanning 1000-fold change, normalized to 
reference gene Hprt and then normalized to WT controls. Occasional outliers were identified 
using Grubbs’ outlier test and removed.       
 
Adrenal gland histology and analysis. Histology was performed on the adrenal glands of 
the WT and ArcPomc-KO control groups from the ArcPomc:Avpr1b-DKO study. Glands were 
stored in 10% buffered formalin at 4°C, and one gland from each mouse was paraffin-embedded 
in the same orientation by the Morphology and Imaging Module of the University of Michigan 
Vision Core Center. Each gland was cut on a microtome into the center and 6 μm sections 
collected onto glass slides. After drying overnight, slides were deparaffinized, stained with Gill’s 
hematoxylin and eosin (H&E), then dehydrated and coverslipped. An image was taken of a 
representative section from each adrenal under 4X objective using a Nikon 90i upright 
microscope and DS-Fi1 color camera. In each cross-section, two regions of interest, the entire 
adrenal gland and only the medulla, were easily visible from the H&E staining and were outlined 
and the area computed using Elements software (Nikon). From these data the area of the cortex 
was calculated (total adrenal – medulla).  
 
Immunohistochemistry. For all immunohistochemistry, mice were deeply anesthetized 
with 2% tribromoethanol and perfused transcardially with 10% sucrose followed by 4% 
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paraformaldehyde (PFA) in phosphate-buffered saline (PBS) on a pressurized rig (Perfusion 
One; Leica). Whole pituitaries from 8-10 week old mice (n=5 per sex and genotype) were 
collected, post-fixed in 4% PFA for 4 hours then saturated in increasing concentrations of 
sucrose (10%, 20%, 30%) in KPBS for 8-12 hours each at 4°C. Each pituitary was then 
embedded in OCT (Tissue-Tek) in the same orientation and sectioned at 10 μm on a cryostat 
(Leica) at -20°C. Sections from the approximate middle of the gland, containing visible sections 
of all three lobes, were collected directly onto gelatinized slides, dried and frozen at -80°C until 
use. Brains collected from both 8-week old mice (n=5-6 per sex and genotype) and 20-week old 
mice (n=6 per sex and genotype) were postfixed overnight in 4% PFA then saturated in 
increasing concentrations of sucrose (10%, 20%, 30%) in KPBS for 24 hours each at 4°C. Brains 
were sectioned coronally at 30 μm using a freezing microtome stage (Leica) and free-floating 
sections were stored in cryoprotectant solution (25 mM PBS with 30% ethylene glycol and 20% 
glycerol) at -20°C until use.  
Immunostaining was performed on slide-mounted pituitary sections that were thawed for 
one hour and blocked off with a PAP pen (Vector Labs) and on free-floating coronal brain 
sections approximately 120 μm apart according to the same protocol. Tissue was washed three 
times for 15 minutes in KPBS and then incubated overnight at 4°C in KPBS with 0.3% Triton X-
100 (KPBS-T), 2% normal donkey or goat serum and the primary antibody. Primary antibodies 
used were rabbit anti-ACTH (1:5,000, The National Hormone and Peptide Program) and guinea 
pig anti-arginine vasopressin (AVP) (1:1,000, Peninsula Laboratories). Three washes were 
performed and tissue was incubated in the secondary antibody at room temperature for two hours 
(donkey anti-rabbit-FITC or goat-anti-guinea pig-FITC, 1:500, Invitrogen). Following additional 
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washes, free-floating brain sections were then mounted on gelatin coated glass slides and all 
slides were coverslipped using ProLong Antifade Gold (Invitrogen). 
 
Imaging and Analysis. Sections were imaged using a Nikon 90i upright microscope 
equipped with an X-Cite 120Q fluorescent light source and CoolSNAP HQ2 CD camera 
(Photometrics) and a 4X (pituitary) or 10X (brain) objective. Fluorescent signals were detected 
using a 488 excitation/525 emission filter cube and images were recorded from all sections using 
a constant exposure time (1.5 s for ACTH, 900 ms for AVP). All post-image analyses were 
performed in ImageJ (204). In the pituitary, one representative section from each animal was 
chosen, each lobe outlined manually and the mean intensity and size calculated. To calculate 
ACTH signal intensity of the anterior lobe, the mean intensity of the posterior lobe (considered 
background) was subtracted from the mean intensity of the anterior lobe and multiplied by its 
size. In the brain, four consecutive sections of PVH were imaged utilizing rostral-caudal 
coordinates obtained from the Mouse Brain Atlas (205) of Bregma -0.70 to -1.06.  Each section 
of PVH was manually outlined along with a background square lateral to the PVH where no 
signal was visible. The mean background pixel intensity was subtracted from the mean intensity 
of the PVH and the signal intensities from each of the four sections per animal were added. 
 
In situ hybridization. [35S]-cRNA antisense riboprobes to mouse Crh (206) and rat Avp 
(207) were prepared from previously described plasmids. The plasmids were linearized with 
HindII (Crh) or EcoRI (Avp) and 1 μg of each linearized plasmid was used for in vitro 
transcription with Sp6 RNA polymerase (Promega) in the presence of [35S]-labeled UTP (Perkin 
Elmer) to generate the probe. The reactions were allowed to occur for 1.5 hrs at 40°C, remaining 
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template DNA was digested with RNAse-free DNase for 20 minutes at 37°C and the probes were 
purified through Sephadex G-50 Illustra NICK columns (GE Healthcare) as described by the 
manufacturer. Probe radioactivity was counted in a liquid scintillation counter (Perkin Elmer), 
diluted in hybridization buffer (65% formamide, 13% dextran sulfate, 1.3x Denhardt’s solution, 
1.3 mM EDTA, 0.26 M NaCl, 13 mM Tris pH 8) (208) at a concentration of 5 x 106 cpm/mL and 
stored at -20°C in 1 mL aliquots.  
Pair-housed 8-week old mice were euthanized by decapitation within one minute of cage 
disruption at either 9:00 am or 5:00 pm (subsequently time points were collapsed, n= 7-9 per sex 
and genotype). Brains were dissected, flash frozen in isopentane chilled on dry ice, and stored at 
-80°C. Coronal sections containing the PVH were cut at 16 µm on a cryostat (Leica), collected in 
three series on gelatinized slides and stored at -80°C. Hybridization was performed as previously 
described (208). Briefly, sections were fixed for 1 hour in 10% buffered formalin, rinsed in 
KPBS and acetylated in 0.1 M triethanolamine pH 8 containing 0.25% acetic anhydride. Sections 
were then rinsed in 2X saline sodium citrate buffer (SSC) and dehydrated through ascending 
alcohol concentrations. Probe was applied and hybridization was carried out at 60°C for 20 
hours. Sections were then washed in 4X SSC and digested with DNase-free RNase A (10 
µg/mL) for 25 minutes at 37°C. Finally, sections were desalted in washes of increasing 
stringency (from 4X SSC to 0.1X SSC) containing 1 mM dithiothreitol, dehydrated through 
ascending ethanol concentrations and exposed to a storage phosphor screen (Molecular 
Dynamics) for 3 days (Crh) or 1 day (Avp). The screen for Crh was scanned on a Typhoon 9400 
Variable Mode Imager (GE Healthcare) and optical density for PVH of each section quantified 
using ImageQuant software. For Avp, the screen was scanned on a Molecular Imager (BioRad) 
and optical density for PVH of each section quantified using Personal Imager FX. Representative 
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images for data presentation in Figure 3.8 were exposed to BioMax MR film (Kodak), developed 
and scanned into the computer.  
 
Statistics. All data are presented as mean ± SEM. Diurnal corticosterone and qPCR data 
were analyzed with unpaired Student’s t-test between genotypes, and males and females were 
analyzed separately. The hormonal response to stress was analyzed with either repeated 
measures ANOVA (RMANOVA) (corticosterone) or a standard two-way ANOVA (ACTH) 
using genotype and stress as the independent variables. Two-way ANOVA using sex and 
genotype as the independent variables was performed on adrenal weight, adrenal area, and signal 
intensity in the ISH and IHC studies. In the DKO experiment, two-way ANOVA was performed 
with each gene (ArcPomc and Avpr1b) as an independent variable. A significant interaction in an 
RMANOVA was followed by Sidak’s multiple comparison post hoc tests whereas a significant 
interaction in a standard two-way ANOVA was followed by Tukey’s multiple comparison post 
hoc tests. All analyses were performed in Prism 6 (GraphPad). 
 
Results 
 
The HPA axis of ArcPomc-KO mice is dysregulated in a sex- and age-specific manner.  
In an effort to separate a primary effect of ArcPomc on the HPA axis from a secondary 
effect that could be due to obesity or metabolic complications, we measured plasma 
corticosterone concentrations at the diurnal peak (~5:00 pm) and nadir (~9:00 am) both before 
and during the initial onset of obesity. ArcPomc-KO mice started to weigh statistically more than 
WT littermates at age 5-6 weeks, as described previously (86). At 2 weeks of age all mice had 
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relatively low corticosterone levels at the diurnal peak (Figure 3.1A). This likely reflects that the 
mice were still in the stress hyporesponsive period, which is characterized by low levels of 
circulating corticosterone and is believed to end between postnatal days 9 and 18 in mice 
(209,210). Starting at age 4 weeks, before the onset of obesity in ArcPomc-KO mice, male 
ArcPomc-KO mice had elevated corticosterone specifically at the diurnal peak whereas female 
ArcPomc-KO mice were identical to controls (Figure 3.1A). At the diurnal nadir, female 
ArcPomc-KO mice had elevated corticosterone at age 4 weeks, which normalized by age 6 
weeks, whereas male ArcPomc-KO had a trend toward elevated corticosterone levels across all 
ages (Figure 3.1B).  
We next subjected a naïve cohort of 8-week old mice to restraint stress (Figure 3.2). Mice 
of both sexes and genotypes responded to the stressor with a rise in corticosterone. In males, 
although basal corticosterone levels were not different, ArcPomc-KO mice showed an 
exaggerated elevation of corticosterone after stress. On the other hand, there was no effect of 
genotype in females (Figure 3.2A). ACTH levels were increased in all groups by exposure to a 
stressor but there was no effect of genotype in either sex (Figure 3.2B).  
To assess how this HPA phenotype was affected by age and/or obesity, we repeated the 
restraint stress experiment in a separate cohort of 4-6 month, obese ArcPomc-KO mice and WT 
controls. Basal evening corticosterone levels showed the same pattern as in younger mice. 
Female ArcPomc-KO mice had the same levels as controls (WT, 118 ± 19 ng/mL; ArcPomc-KO, 
114 ± 16 ng/mL) and male ArcPomc-KO mice exhibited elevated corticosterone (WT, 46 ± 5 
ng/mL; ArcPomc-KO, 138 ± 21 ng/mL; t(9) = 2.6, P < 0.05). In all groups, restraint stress in the 
morning caused a significant increase in corticosterone. In males, ArcPomc-KO mice had higher 
corticosterone than WT both before and after stress, whereas female ArcPomc-KO mice had 
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increased basal corticosterone but a normal response to stress (Figure 3.3A). Restraint stress also 
caused a significant increase in plasma ACTH in all groups. Interestingly, in both sexes, 
ArcPomc-KO mice showed a blunted ACTH response to stress compared to WT although basal 
ACTH levels were not different (Figure 3.3B). 
 
ArcPomc-KO mice exhibit an anxiety-like behavioral phenotype 
 The best-characterized anxiety tests require approximately equal levels of locomotion in 
the study groups, but ArcPomc-KO mice were hypolocomotive as they become obese, as 
discussed in Chapter 2. We therefore performed anxiety tests on a group of young, pre-obese 
mice as well as a group of older, obese mice. In the open field, all of the young mice ran 
approximately the same total distance (Male WT: 46.9 ± 8.4 m; Male ArcPomc-KO: 34.4 ± 5.0 
m; Female WT: 36.7 ± 8.2 m; Female ArcPomc-KO: 34.9 ± 3.2 m) but ArcPomc-KO mice of 
both sexes spent less time in the center of the field, suggesting an anxious phenotype (Figure 
3.4A). The same effect held true in older, obese ArcPomc-KO mice, but their total distance 
traveled in the open field was less than controls (Male WT: 38.2 ± 4.2 m; Male ArcPomc-
KO:17.5 ± 1.6 m ; Female WT: 42.8 ± 2.1 m ; Female ArcPomc-KO: 24.6 ± 5.3 m; Effect of 
genotype in 2-way ANOVA: F(1,24) = 26.0, P < 0.001). 
 We next tested anxiety using the elevated plus maze. In young, pre-obese mice, there was 
no genotype difference in the amount of time spent in the open arms of the maze (Figure 3.4B). 
However, in the older cohort, ArcPomc-KO mice spent significantly less time in the open arms, 
indicating an anxious phenotype. Whether this result represents true anxiety or is an artifact of 
the hypolocomotion in the obese mice is difficult to determine. To test for a depressive 
phenotype, we also performed the forced swim test. In both the young and older cohorts, there 
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were no group differences in the amount of time that each mouse spent floating versus struggling 
or swimming, indicating that ArcPomc-KO mice do not have a depressive phenotype (data not 
shown). 
 Lastly, we performed the novelty-suppressed feeding test, reasoning that the presumably 
higher drive for food in the obese mice may overcome their general hypolocomotive phenotype. 
This test was performed in 8 week old mice, which are beginning to become obese but are not 
yet morbidly so. Surprisingly, we found that, although all the mice approached the food during 
the 10-minute test session (data not shown), only one of the 15 ArcPomc-KO mice started to eat 
the food. This is in stark contrast to WT controls, which ate the food in an average of about 5 
minutes (Figure 3.4C). All mice ate food within 5 minutes of returning to the home cage. These 
results support the findings of the open field and suggest that ArcPomc-KO mice exhibit an 
anxious phenotype even at a young age.  
 
ArcPomc-KO mice have an enlarged adrenal cortex 
Because basal plasma corticosterone was elevated and corticosterone rose 
disproportionately to ACTH after restraint stress in ArcPomc-KO male mice, we next examined 
the adrenal glands. Females had heavier adrenals than males regardless of genotype, and 
ArcPomc-KO mice of both sexes had heavier adrenals than WT controls (Figure 3.5A). To 
confirm that adrenal enlargement was not simply due to body weight increase, we also measured 
adrenal weight in a separate group of ArcPomc-KO mice matched to body weight of WT by 
caloric restriction. Because food restriction is a stressor itself, we restricted WT mice to 85% of 
their body weight as a control. Even under these conditions, ArcPomc-KO mice of both sexes 
had heavier adrenals than WT (Figure 3.5B). H&E staining of representative adrenal cross-
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sections from 16-week old obese mice are shown (Figure 3.5C). There was no difference 
between groups in the area of the medulla. In WT mice, cortical area was larger in female than 
male mice, and ArcPomc-KO mice of both sexes had significantly larger adrenocortical area than 
WT controls, but there was no sex difference (Figure 3.5D). Semi-quantitative RT-PCR of whole 
adrenal gland in obese males revealed up-regulation of several cortex-specific genes involved in 
ACTH signaling and glucocorticoid biosynthesis in the ArcPomc-KO mice, including the ACTH 
receptor (Mc2r), melanocortin receptor accessory protein (Mrap), steroidogenic factor-1 
(Nr5a1), and 11-β-hydroxylase (Cyp11b1), as well as down-regulation of two medulla-specific 
genes involved in catecholamine synthesis, tyrosine hydroxylase (Th) and phenylethanolamine-
N-methyltransferase (Pnmt) (Figure 3.5E). 
 
Increased expression of ACTH secretagogue receptors in the anterior pituitary of ArcPomc-KO 
mice  
 Enlarged adrenocortical area is most often caused by chronic over-stimulation of the 
adrenal by circulating ACTH. Immunostaining for ACTH in whole pituitary glands (Figure 
3.6A) showed no differences between groups in anterior lobe size or number of corticotrophs 
(data not shown) nor in the intensity of staining in the anterior lobe (Figure 3.6B). Semi-
quantitative RT-PCR was used to compare mRNA levels in the anterior lobe from mice at two 
ages. mRNA levels of corticotropin releasing hormone receptor 1 (Crhr1) and vasopressin 
receptor 1b (Avpr1b) were increased at both ages 8 weeks and 16 weeks in male ArcPomc-KO 
mice, whereas female ArcPomc-KO mice only showed elevated Crhr1 levels at 16 weeks 
(Figure 3.6C,D). Pomc mRNA levels were not different between genotypes at either age. In 
females, CRH binding protein (Crhbp) levels were decreased in ArcPomc-KO mice at both ages. 
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 Hypothalamic arginine vasopressin is increased in ArcPomc-KO mice  
 Semi-quantitative RT-PCR was also used to assay hypothalamic gene expression at age 8 
weeks and 16 weeks. At age 8 weeks, hypothalamic mRNA levels of Crh, Avp, glucocorticoid 
receptor (Nr3c1), and Crhbp were not different between genotypes, but neuropeptide Y (Npy) 
was significantly lower in ArcPomc-KO mice of both sexes than in WT controls (Figure 3.7A). 
At age 16 weeks, Npy was still decreased in ArcPomc-KO mice. In addition, Avp was 
significantly increased in ArcPomc-KO mice of both sexes, whereas Crh was increased only in 
males (Figure 3.7B).  
To confirm the gene expression changes identified in the hypothalamus and to increase 
our spatial resolution, we performed in situ hybridization (ISH) for Crh and Avp in unstressed 8-
week old mice. In the PVH, no differences between genotypes were found in the intensity of Crh 
signal, whereas Avp signal intensity was elevated in the PVH of ArcPomc-KO mice (Figure 
3.8A,B). Using immunohistochemistry (IHC) to semi-quantitatively compare protein levels, we 
found that the PVH in ArcPomc-KO of both sexes had more intense staining for AVP than WT, 
and female ArcPomc-KO mice had even higher staining intensity than male ArcPomc-KO mice, 
although no sex difference was apparent in WT animals (Figure 3.8C,D). The numbers of cells 
positive for AVP per PVH was not different between groups (data not shown).  
 
V1bR signaling does not mediate the dysregulated HPA axis of ArcPomc-KO male mice 
 To test the role of elevated AVP in the dysregulated HPA axis of ArcPomc-KO mice, we 
generated a double knockout also lacking the vasopressin 1B receptor (ArcPomc:Avpr1b-DKO). 
At age 16 weeks, in both sexes, mice possessing the ArcPomc-KO allele had heavier adrenals 
85
than WT regardless of Avpr1b genotype. In females, Avpr1b-KO was associated with a slight but 
significant decrease in adrenal weight consistent with the original report of these mice (203), but 
there was no interaction with the ArcPomc allele (Figure 3.9A). 
 Non-stressed plasma samples were taken for corticosterone analysis at the circadian peak 
at multiple ages between 6 and 16 weeks (Figure 3.9B). Male mice lacking the ArcPomc gene 
had higher corticosterone at each time point measured regardless of Avpr1b genotype, whereas 
there were no differences in females. Lack of V1br was associated with increased corticosterone 
in males at age 8 weeks but a decrease in females at age 16 weeks. 
 Finally, we studied the hormonal response of the DKO mice to restraint stress (Figure 
3.9C). In males, in agreement with Figure 3.3A, baseline morning plasma corticosterone levels 
were elevated in mice possessing the ArcPomc-KO allele, whereas there was no difference in 
females and no effect of the Avpr1b allele. Following 20 minutes of restraint stress, 
corticosterone levels were significantly elevated from baseline in all four groups. In males, mice 
lacking the ArcPomc allele had higher corticosterone stress response than those with the WT 
allele. Additionally, there was a decrease in the corticosterone response to stress specifically in 
Avpr1b-KO mice as related to WT, whereas the Avpr1b allele did not affect corticosterone in 
mice lacking ArcPomc. In females, surprisingly, both the ArcPomc-KO and Avpr1b-KO allele 
were associated with a slightly decreased corticosterone stress response. 
 
Discussion 
 
Using genetic mouse models coupled with an array of molecular biological techniques, 
we have identified ArcPomc as an important regulator of the HPA axis. Furthermore, we have 
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proven that this regulation, although associated with changes in hypothalamic vasopressin levels, 
does not depend on signaling via V1br. These data support and significantly expand upon 
previous data from our laboratory that used a similar genetic model for ArcPomc-deficiency. Our 
results suggest that ArcPOMC may have two distinct roles in the regulation of the HPA axis. 
First, it appears to be necessary to masculinize the HPA axis in development. Second, ArcPOMC 
may be involved in the control of the HPA axis by metabolic signals such as insulin and leptin.  
Sexual dimorphism of the HPA axis, wherein adult females have higher corticosterone 
levels than males both basally throughout the circadian cycle and in response to a stressor, has 
been well characterized in rats and mice (for review, see (211)). The ontogeny of these sex 
differences is poorly understood, although it is generally accepted that the HPA axis is 
intrinsically feminine and can be masculinized by a perinatal testosterone surge (212). 
Testosterone can signal via the androgen receptor (AR) or it can be converted to estradiol, by 
aromatase, and signal via the estrogen receptors (ER-α, ER-β). Indeed, studies in rats have 
implicated an organizational role for both testosterone and estrogen signaling in the 
masculinization of the HPA axis (213), but the neural mechanism is completely unknown.  
The sexual dimorphism of basal corticosterone has been reported as early as age 5 weeks 
in mice (214). Many studies measure basal corticosterone in the morning, close to the diurnal 
nadir, but sex differences are more easily apparent closer to the diurnal peak (215). By analyzing 
corticosterone at both time points, we have extended these previous results by reporting a sex 
difference in plasma corticosterone in WT mice at 4 weeks of age. Starting at this age, the 
plasma corticosterone level of male ArcPomc-KO mice was significantly elevated from WT 
male but indistinguishable from female mice. This suggests that ArcPOMC is necessary for the 
masculinization of the HPA axis in development.  
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A possible role for ArcPOMC in the sexual differentiation of the brain has not been 
previously explored. In adult mice there are only approximately 3,000 POMC neurons in the Arc 
(5), but Pomc is expressed transiently during mid-gestation in Arc progenitor cells that go on to 
become AGRP or kisspeptin-positive and POMC-negative (51,53). Almost all ArcPOMC 
neurons in development, starting at embryonic day 15.5 (e15.5), express ER-α, which can bind to 
the upstream neuronal enhancer region of the Pomc gene in vitro (40). Additionally, many Arc 
neurons express AR by e15.5 (216). In adult rats, Pomc expression is positively regulated by 
testosterone following its conversion to estradiol (201,217), but similar experiments have not 
been reported in neonatal mice. Thus ArcPOMC neurons in development, regardless of whether 
they express Pomc in adulthood, could be directly stimulated by the perinatal testosterone surge 
and play an important role in the masculinization of the HPA axis.  
Neuropsychiatric disorders such as depression and anxiety are more prevalent in females 
than males and can be associated with an elevated HPA axis as well as obesity. To determine 
whether ArcPomc-KO mice had a depressed or anxious phenotype, we performed a battery of 
behavioral tests. Using the forced swim as a measure of depression, we found that the ArcPomc-
KO mice did not exhibit a depressive phenotype. To control for the hypolocomotion apparent in 
obese ArcPomc-KO mice, we performed anxiety tests in both young, pre-obese mice as well as 
older, obese mice. The results from the open field and, particularly, the novelty-suppressed 
feeding tests suggest that ArcPomc-KO mice exhibit an anxious phenotype even from a young 
age. The fact that young ArcPomc-KO mice of both sexes show the same phenotype suggests 
that the anxiety may not be due to a dysregulated HPA axis or obesity. Rather, melanocortin 
signaling in the brain may directly act as an anxiolytic, although there are some studies 
suggesting the opposite (218).  
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As early as 2 months of age, both male and female ArcPomc-KO exhibited adrenocortical 
hypertrophy and by 4-6 months they showed a relative flattening of the diurnal HPA rhythm due 
to increased nadir corticosterone levels as well as a decreased ACTH, but normal or exaggerated 
corticosterone, response to stress. Rodent models of type I and type II diabetes mellitus (DM) 
which lack insulin and leptin, respectively, show a similar array of HPA abnormalities. 
Peripheral injection of streptozotocin (STZ) selectively kills the pancreatic β-cells, results in 
hypoinsulinemia and hyperglycemia, and is used as a model for type I DM (219). STZ-treated 
diabetic rats exhibited elevated ACTH and corticosterone particularly at the diurnal nadir and a 
blunted rise in ACTH and corticosterone upon stimulation by a stressor, all of which was 
normalized by administration of exogenous insulin (220-224). Leptin-deficient ob/ob mice, 
which are morbidly obese and are used as a model of type II DM (134), showed increased 
adrenocortical volume (225-227) and elevated corticosterone both basally throughout the diurnal 
cycle and in response to stress (135-137,228). Treatment of ob/ob mice with exogenous leptin 
decreased but did not normalize basal and stressed corticosterone levels (229,230), and leptin 
decreased the corticosterone response to fasting and restraint stress in WT mice (231,232).  
ArcPomc-KO mice are not considered a model of DM because, although they are 
hyperleptinemic, hyperinsulinemic and insulin resistant, fasting blood sugar is relatively normal 
(86). Indeed, although there is a tight relationship between hyperglycemia and HPA 
overactivation, causing many groups to assume causality, at least one study has reported that 
hyperglycemia is not necessary for HPA axis dysregulation in type I DM (233). Rather, HPA 
dysregulation in DM could be due to altered signaling by leptin and/or insulin and independent 
of blood glucose levels. Approximately 70% of ArcPOMC neurons express leptin receptor 
(LepR) and are activated by leptin (5,34). ArcPomc neurons also express insulin receptor (InsR) 
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and insulin stimulates Pomc expression (38). Thus it is possible that leptin and/or insulin could 
directly activate ArcPOMC neurons and thereby inhibit the HPA axis. However, mice lacking 
either the LepR or the InsR or both specifically on cells expressing Pomc have been reported to 
have normal basal and stressed corticosterone levels, so it is also possible that leptin and/or 
insulin could activate ArcPOMC neurons indirectly (47,234,235). Supporting this idea, mice 
lacking InsR in the whole hypothalamus showed elevated basal and stressed corticosterone, a 
phenotype that was somewhat recapitulated when InsR was ablated only from AGRP neurons 
(236). Thus our current study suggests that ArcPOMC neurons may integrate leptin and insulin 
signaling onto the HPA axis and that leptin and/or insulin resistance at the level of the Arc could 
contribute to HPA dysregulation seen in DM.  
Other studies have identified NPY, which is co-expressed in AGRP neurons in the Arc, 
as a neuropeptide that is inhibited by insulin and leptin and can activate the HPA axis 
(230,231,237-239). Npy is upregulated in the hypothalamus of both STZ-treated rats and ob/ob 
mice (240-242), suggesting that elevated NPY may play a role in the hyperactivation of the HPA 
axis in DM. In ArcPomc-KO mice, hypothalamic Npy levels are markedly decreased below those 
of WT even at a young age. It seems likely that the decreased Npy levels are a direct result of 
hyperleptinemia, but this phenotype needs to be explored further. The fact that similar HPA 
phenotypes are observed in models that are associated with either marked increase or marked 
decrease in hypothalamic NPY suggests that there are parallel pathways by which insulin and/or 
leptin can affect the HPA axis at the level of the Arc. Alternatively, STZ-treated rats and ob/ob 
mice also showed markedly decreased hypothalamic Pomc (243,244), and the lack of inhibitory 
POMC could activate the HPA axis independently of NPY. Npy-KO mice have normal 
corticosterone (245,246). Interestingly, deletion of the NPY receptor 2 from ob/ob mice 
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increases arcuate Pomc mRNA and normalizes corticosterone levels, suggesting POMC could be 
downstream of the effects of NPY on the HPA axis (247).  
The initial cause of the dysregulation of the HPA axis in DM is unclear, but constantly 
elevated corticosterone acts as a chronic stressor. AVP has been shown to play an important role 
in regulating ACTH release in several models of chronic stress (248,249). Both STZ-treated rats 
and ob/ob mice, along with the ArcPomc-KO mice, had increased expression of Avp mRNA in 
the hypothalamus (250,251). To test the role of AVP signaling via pituitary V1bR in the 
dysregulated HPA axis of ArcPomc-KO mice, we crossed these mice with Avpr1b-KO mice. In 
agreement with previously published results, we found that female, but not male, mice 
homozygous for the Avpr1b-KO allele had slightly decreased adrenal gland size, and 
homozygous mice of both sexes had a somewhat blunted corticosterone response to stress (203). 
However, these differences were not affected by ArcPomc genotype and deletion of the Avpr1b 
gene did not rescue the increased adrenal size and elevated corticosterone levels of ArcPomc-KO 
mice. Therefore we conclude that HPA dysregulation in ArcPomc-KO mice occurs 
independently of AVP signaling via the V1bR despite upregulation of AVP in the hypothalamus 
and Avpr1b in the pituitary of these mice. In agreement with our results, Brattleboro rats, which 
do not produce AVP, showed the same increase in adrenal size and plasma corticosterone 
following STZ treatment as did normal rats (252). 
 Having eliminated AVP, it is likely that CRH is the downstream factor inducing 
dysregulation in the HPA axis of ArcPomc-KO mice. Crhr1 mRNA in the anterior pituitary was 
also increased in male ArcPomc-KO mice at both ages studied and in older female ArcPomc-KO 
mice. In the hypothalamus, elevated Crh was seen only in older male ArcPomc-KO mice. 
Further experiments will be necessary to confirm and characterize a role for CRH in the 
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described HPA phenotype. Interestingly, specifically in females, Crhbp levels were markedly 
downregulated in the anterior pituitary of ArcPomc-KO mice. This is likely secondary to 
disruption of the hypothalamic-pituitary-gonadal axis. Although we did not measure plasma 
estrogen directly, the uterine weight of ArcPomc-KO mice is approximately half that as WT 
(unpublished observation), indicating decreased estrogen levels. CRH-BP has been shown to be 
positively regulated by estrogen (253,254).  
Because the HPA phenotype of ArcPomc-KO mice described herein does not occur in β-
endorphin-KO mice (184), we posit that it is caused specifically by lack of melanocortin 
signaling in the brain, where melanocortins signal via two known receptors, the melanocortin 3 
and 4 receptors (Mc3r, Mc4r). As mentioned above, acute central injection of Mc3r/Mc4r 
agonists activated the HPA axis in rats (168,170,171,174). This activation could be prevented by 
pretreatment with an Mc4r-specific antagonist (170), and Mc4r-KO rats showed a reduced HPA 
response to restraint stress (177). Together, these studies suggest that signaling via the Mc4r can 
activate the HPA axis, whereas our data shows that elimination of the endogenous agonist of the 
Mc4r activates the HPA axis. The discrepancy here could be explained by a species-specific 
difference in the role of POMC on the HPA axis. Knockout mice of each receptor have been 
generated, but the HPA axis of these knockouts has not been well characterized beyond reports 
of normal basal corticosterone at a single time point (25-27). Alternatively, the phenotype we 
have described in this study is likely due to a combined loss of signaling at both Mc3r and Mc4r 
and suggests that Mc3r may be more important in regulation of the HPA axis than previously 
acknowledged.  
  In conclusion, in addition to its well-characterized roles in feeding behavior and energy 
expenditure, ArcPomc is involved in regulation of anxious behavior and the HPA axis. Mice 
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lacking ArcPomc show an anxious phenotype and have a hyperactivated HPA axis as indicated 
by elevated basal and stress-induced corticosterone levels and adrenal hypertrophy. Although 
these mice also have elevated hypothalamic AVP as well as increased expression of Avpr1b in 
the anterior pituitary, signaling via this pathway is not necessary for the hyperactive HPA axis 
observed. Together these results suggest neural melanocortins as a novel target that tonically 
inhibits the HPA axis as well as prevents anxious behavior. 
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Table 3.1: Primers used for semi-quantitative RT-PCR analysis of the HPA axis. 
 
Gene 
Symbol Gene Name 
Forward Primer, 
5’-3’ 
Reverse Primer,  
5’-3’ 
Avp Arginine vasopressin TCGCCAGGATGC
TCAACAC 
TTGGTCCGAAGC
AGCGTC 
Avpr1b Arginine vasopressin receptor 
1b 
ATCCGAACCGTG
AAGATGAC 
CAGAAGCATCGA
GATGGTGA 
Crh Corticotropin releasing 
hormone 
CACCTACCAAGG
GAGGAGAA 
GCGGGACTTCTG
TTGAGATT 
Crhbp Corticotropin releasing 
hormone binding protein 
ATGATGCCCTTA
GCAGACCTGTGT
TAC 
CAAATGTCACAC
GGTTAATGTGTT
TCC 
Crhr1 Corticotropin releasing 
hormone receptor 1 
CGCAAGTGGATG
TTCGTCT 
GGGGCCCTGGTA
GATGTAGT 
Cyp11b1 Cytochrome P450, family 11, 
subfamily b, polypeptide 1 
CTCCATGTTCAA
AACCACCA 
CTGCCAGCTCTC
GATACACA 
Hprt Hypoxanthine-guanine 
phosphoribosyltransferase 
GATTAGCGATGA
TGAACCAGGTT 
CCTCCCATCTCC
TTCATGACA 
Mc2r Melanocortin-2 receptor 
(ACTH receptor) 
GTGACAAAGCCA
AGGAGAGG 
TGGTGTTTGCCG
TTGACTTA 
Mrap Melanocortin 2 receptor 
accessory protein 
CCGCTCACCAGC
TATGAGTA 
AGAAAGAGGAG
CACCACGAA 
Npy Neuropeptide Y GTGTGTTTGGGC
ATTCTGG 
TGTCTCAGGGCT
GGATCTCT 
Nr3c1 
 
Glucocorticoid receptor 
 
AGGCCGCTCAGT
GTTTTCTA 
ACACGTCAGCAC
CCCATAAT 
Nr5a1 Steroidogenic factor 1, Sf-1 ATCTACCGCCAG
GTCCAGTA 
GCATGCAACTGG
AGCACTAA 
Pnmt Phenylethanolamine-N-
methyltransferase 
AGACCTGAGCAA
CCCTGATG 
TGGTGATGTCCT
CAAAGTGG 
Pomc Proopiomelanocortin GAGCTGGTGCCT
GGAGAG 
TTTTCAGTCAGG
GGCTGTTC 
Th Tyrosine hydroxylase TGAAGCCAAAAT
CCACCACT 
TGACACTTTCCT
TGGGAACC 
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Figure 3.1: Diurnal rhythm of plasma corticosterone during development in ArcPomc-
KO mice. In both panels, male (left) and female (right) data are shown. A, Unstressed corticos-
terone levels at the diurnal peak (5:00 pm) from ages 2-8 weeks. Analysis of each time point 
by unpaired Student’s t-test between genotypes showed that male ArcPomc-KO mice had 
higher corticosterone than WT at ages 4-8 weeks (4 weeks, t(18) = 3.4; 6 weeks, t(18) = 3.1; 8 
weeks, t(18) = 3.4). B, Unstressed corticosterone levels at the diurnal nadir (9:00 am) from age 
4-8 weeks. Two-way ANOVA revealed a strong trend towards a genotype effect in males 
(F(1,54) = 4.0, P = 0.051). Analysis of each time point by unpaired Student’s t-test between 
genotypes showed that female ArcPomc-KO mice had higher corticosterone than WT at age 4 
weeks (t(19) = 2.6). N = 9-10 per sex, genotype and age. * P < 0.05; ** P < 0.01 by unpaired 
Student’s t-test between genotypes.
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Figure 3.2: Hormonal stress response of young ArcPomc-KO mice. In both panels, male 
(left) and female (right) data are shown. A, Corticosterone levels before (basal) and immedi-
ately following a 20-minute restraint stress. In males, RMANOVA revealed a significant main 
effect of genotype (F(1,14) = 5.0), stress (F(1,14) = 421.3), and an interaction (F(1,14) = 5.7), 
whereas in females there was only a main effect of stress (F(1,14) = 127.2). B, ACTH levels in 
unstressed and stressed mice. Two-way ANOVA revealed only a significant main effect of 
stress (Male: F(1,27) = 11.9; Female: F(1,28) = 24.2) but not genotype. N = 8 per sex, genotype 
and condition. ** P < 0.01 by Sidak’s post-hoc comparison test.
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Figure 3.3: Hormonal stress response of older, obese ArcPomc-KO mice. In both panels, 
male (left) and female (right) data are shown. A, Corticosterone levels before (basal) and 
immediately following a 20-minute restraint stress. In males, RMANOVA revealed a signifi-
cant effect of genotype (F(1,10) = 40.4) and stress (F(1,10) = 40.7) but no interaction. In 
females, there was a significant effect of stress (F(1,9) = 24.1) and an interaction (F(1,9) = 
10.3). B, ACTH levels in unstressed and stressed mice. Two-way ANOVA in males revealed a 
significant effect of genotype (F(1,16) = 6.5), stress (F(1,16) = 17.9) and an interaction 
(F(1,16) = 7.4).  In females, there was a significant effect of stress (F(1,23) = 45.2) and an 
interaction (F(1,23) = 11.2). N = 5-6 per sex and genotype (Panel A) and 3-9 per sex, genotype 
and condition (Panel B). * P < 0.05; ** P < 0.01 by Sidak’s (Panel A) or Tukey’s (Panel B) 
post-hoc comparison test.
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Figure 3.4: Behavioral anxiety tests in ArcPomc-KO mice. In all panels, data from separate 
cohorts of young, pre-obese (left) and older, obese (right) mice are shown. A, Percentage of 
time spent in the center of an open field. In both groups, two-way ANOVA revealed only a 
significant effect of genotype (Pre-obese: F(1,24) = 4.3; Obese: F(1,24) = 8.8) but not of sex 
or an interaction. B, Percentage of time spent in the open arms of the elevated plus maze. Two-
way ANOVA in the young, pre-obese mice showed only an effect of sex (F(1,24) = 10.7) 
whereas in the obese mice there was only a significant effect of genotype (F(1,24) = 12.6).  C, 
Latency to eat in the novelty-suppressed feeding test. Mice that never ate in the 10 minute test 
were assigned a value of 600 s. Two-way ANOVA revealed a significant effect of genotype 
(F(1,24) = 95.0). N = 5-9 per sex, genotype and condition.
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Figure 3.5: Characterization of adrenal glands of ArcPomc-KO mice A, Weight of adrenal 
glands of 8-week old mice. Two-way ANOVA showed a significant effect of sex (F(1,58) = 
46.7) and genotype (F(1,58) = 147.2) but no interaction. B, Weight of adrenal glands of 30-
week old WT mice calorie restricted to 85% of body weight and ArcPomc-KO mice matched 
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to starting body weight of WT. Two-way ANOVA found a significant effect of sex (F(1,28) =  
9.0) and genotype (F(1,28) = 29.1) but no interaction. C, Representative H&E-stained cross-
sections of adrenal glands from 16-week old mice, where the outline of the medulla is indi-
cated by a dotted line. D, Quantification of the area of the medulla was not different between 
groups, whereas two-way ANOVA of cortical area revealed a significant effect of genotype 
(F(1,20) = 124.6) and an interaction (F(1,20) = 5.1). E, Semi-quantitative RT-PCR of adrenal 
glands from 5-6 month old male mice. Data were analyzed by unpaired Student’s t-test 
between genotypes: Mc2r, t(14) = 4.2; Mrap, t(14) = 8.4; Nr5a1, t(14) = 4.3; Cyp11b1, t(14) = 
6.3; Th, t(14) = 4.1; Pnmt, t(14) = 3.3. N = 16 per sex and genotype (Panel A), 8 per sex and 
genotype (Panel B), 6 per sex and genotype (Panel D) and 8 per genotype (Panel E). * P < 0.05; 
** P < 0.01; *** P < 0.001 by Tukey’s multiple comparisons post hoc test (D) or Student’s 
unpaired t-test between genotypes (E) .
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Figure 3.6: Characterization of pituitary glands of ArcPomc-KO mice. In panels C and D, 
male (left) and female (right) are shown. A, Representative sections of whole pituitary show-
ing immunohistochemistry for ACTH. B, Quantification of intensity of ACTH staining in the 
anterior lobe. Two-way ANOVA showed no differences between groups. C, mRNA levels in 
the anterior lobe of 8-week old mice. Data were analyzed by unpaired Student’s t-test between 
genotypes (Male: Crhr1, t(14) = 4.6; Avpr1b, t(14) = 3.8; Female: Crhbp, t(14) = 3.6)  D, 
mRNA levels in the anterior lobe of 16-week old mice. Data were analyzed by unpaired 
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Student’s t-test between genotypes (Male: Crhr1, t(10) = 2.4; Avpr1b, t(10) = 3.0; Female: 
Crhr1, t(13) = 2.2; Crhbp, t(15) = 9.1). N = 5 per sex and genotype (Panel B) and 7-8 per sex, 
genotype and age (Panels C,D). * P < 0.05; ** P < 0.01; *** P < 0.001 by unpaired Student’s 
t-test between genotypes.
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Figure 3.7: Characterization of the hypothalamus of ArcPomc-KO mice. In both panels, 
male (left) and female (right) data are shown. A, mRNA levels in the whole hypothalamus of 
8-week old mice. Data were analyzed by unpaired Student’s t-test between genotypes (Male: 
Npy, t(12) = 6.6; Female: Npy,  t(15) = 3.8). B, mRNA levels in the whole hypothalamus of 
16-week old mice. Data were analyzed by unpaired Student’s t-test between genotypes (Male: 
Npy, t(13) = 4.2, Avp, t(15) = 3.8, Crh, t(15) = 3.5; Female: Npy, t(15) = 4.0, Avp, t(16) = 5.6]. 
N = 7-8 per sex, genotype and age. ** P < 0.01; *** P < 0.001 by unpaired Student’s t-test 
between genotypes.
A
Crh Avp Nr3c1 Crhbp Npy
0
50
100
150
200
m
R
N
A
 L
ev
el
 
(%
 o
f W
T
)
***
Crh Avp Nr3c1 Crhbp Npy
0
50
100
150
200
m
R
N
A
 L
ev
el
 
(%
 o
f W
T
)
**
**
**
Crh Avp Nr3c1 Crhbp Npy0
50
100
150
200
**
Crh Avp Nr3c1 Crhbp Npy0
50
100
150
200
**
***
8-wk Male
16-wk Male
8-wk Female
16-wk FemaleB
WT
ArcPomc-KO
WT
ArcPomc-KO
103
Figure 3.8: Paraventricular hypothalamus of ArcPomc-KO mice. A, Representative 
images of Crh and Avp ISH in both genotypes. B, Quantification of Crh and Avp signal inten-
sity only in the PVH in all four groups. Two-way ANOVA of Crh signal showed no differences 
between groups while two-way ANOVA of Avp signal revealed a significant main effect of 
genotype (F(1,26) = 86.7). C, Representative images of AVP IHC in the PVH of mice from 
both genotypes. D, Quantification of total PVH signal in all four groups. Two-way ANOVA 
revealed a significant main effect of sex (F(1,20) = 11.7), genotype (F(1,20) = 152.4), and an 
interaction (F(1,20) = 5.3). N = 5-9 per sex and genotype. * P < 0.05 by Tukey’s multiple com-
parisons post hoc test. CeA, central amygdala; SON, supraoptic nucleus; SCN, suprachias-
matic nucleus; 3v, third ventricle.
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Figure 3.9: HPA axis of ArcPomc:Avpr1b-DKO mice. Male (left) and female (right) data are 
shown. A, Adrenal weights of 16-week old mice. Two-way ANOVA using each gene as an 
independent variable revealed a significant effect of ArcPomc in males (F(1,23) = 52.3) and of 
both genes in females (ArcPomc, F(1,23) = 96.9; Avpr1b, F(1,23) = 5.7) but no interaction. B, 
Unstressed evening corticosterone levels from age 6 weeks to 16 weeks. Two-way ANOVA 
revealed a significant effect of ArcPomc gene at each time point in males (6 weeks, F(1,20) = 
4.4; 8 weeks, F(1,23) = 29.7; 12 weeks, F(1,23) = 4.6; 16 weeks, F(1,23) = 35.9). There was a 
significant effect of Avpr1b genotype in males at age 8 weeks (F(1,23) = 4.4, P < 0.05) and in 
females at age 16 weeks (F(1,23) = 7.7, P < 0.05) (not indicated on graph). C, Corticosterone 
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levels before (basal) and immediately following a 20-minute restraint stress in 16-week old 
mice. Two-way ANOVA on basal corticosterone revealed only a significant main effect of 
ArcPomc gene in males (F(1,23) = 10.5) and no differences between groups in females. Two-
way ANOVA on stressed corticosterone revealed a significant main effect of ArcPomc (F(1,23) 
= 18.2) as well as a significant interaction (F(1,23) = 7.7) in males and in females there was a 
significant effect of both ArcPomc (F(1,23) = 20.3) and Avpr1b (F(1,23) = 7.5, P < 0.05) but 
no interaction. N = 6-8 per sex, genotype and condition. * P < 0.05 by Tukey’s post hoc com-
parison test. 
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Chapter 4: Summary, Conclusions and Future Directions 
   
Hypothalamic POMC has been extensively studied over the last 30 years for its critical 
roles in feeding behavior and energy expenditure. Using a genetic knockout mouse model that 
does not express Pomc specifically in the Arc, I have provided here extensive evidence that 
hypothalamic POMC-derived peptides are also involved in regulation of locomotor activity 
levels and the HPA stress axis.  
In Chapter 2, I showed that ArcPomc-KO mice exhibited hyperphagic obesity and very 
low levels of spontaneous home cage locomotor activity. Reversing the obesity by caloric 
restriction over a period of several weeks normalized spontaneous home cage activity levels, 
suggesting that the originally observed decreased levels were secondary to obesity, leading me to 
conclude that ArcPOMC does not play a direct role in regulating spontaneous activity levels. 
Spontaneous and voluntary locomotor activity levels are correlated, and I therefore hypothesized 
that providing young, pre-obese ArcPomc-KO mice with the opportunity to engage in voluntary 
running wheel activity may positively affect the obesity and metabolic outcome. However, male 
ArcPomc-KO mice provided home cage running wheels for 8 weeks showed only negligible 
improvement in body weight and metabolic outcome over control ArcPomc-KO mice without 
wheels, whereas there was no improvement in female ArcPomc-KO mice with access to running 
wheels. This lack of improvement was associated with running wheel activity levels that were 
much lower than WT. Surprisingly, even ArcPomc-KO mice that were prevented from becoming 
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obese by caloric restriction had markedly decreased running wheel activity levels. β-endorphin-
KO mice, on the other hand, exhibited the same level of running wheel activity as controls. From 
these studies, I conclude that ArcPOMC-derived melanocortin peptides, but not β-endorphin, can 
act directly to increase voluntary, but not spontaneous, locomotor activity levels.  
In Chapter 3, I showed that the HPA stress axis of ArcPomc-KO mice was dysregulated 
in a sex-specific manner that worsened with age and/or obesity. Young, pre-obese (4 weeks old) 
male ArcPomc-KO mice had elevated evening peak corticosterone levels that were not different 
from females of either genotype and may reflect a failure of the HPA axis to masculinize in these 
mice. Young adult (8 weeks old) male ArcPomc-KO mice had a normal ACTH but exaggerated 
corticosterone response to restraint stress whereas female ArcPomc-KO mice were not different 
from WT. Additionally, ArcPomc-KO mice of both sexes had enlarged adrenal glands due to 
increased adrenocortical area. Adult (16 weeks old) ArcPomc-KO mice of both sexes were obese 
and had elevated basal morning nadir corticosterone levels and a blunted rise of ACTH, but 
normal or exaggerated increase in corticosterone, in response to restraint stress. ArcPomc-KO 
mice weight-matched to WT controls by caloric restriction and obese ArcPomc-KO mice had 
larger adrenal glands than WT, suggesting that the dysregulation of the HPA axis in older 
ArcPomc-KO mice is not due solely to development of obesity. Rather, the obesity phenotype 
and the dysregulated HPA phenotype caused by the primary genetic insult may both worsen in 
parallel, and thus I conclude that ArcPOMC directly inhibits the HPA stress axis.  
A caveat of these studies is that they were performed exclusively in a single genetic 
knockout mouse model, which by its nature reveals only the phenotype that occurs in an animal 
in the complete absence of the gene. To fully understand the physiological functions of 
ArcPOMC neurons and the mechanisms by which they occur, these types of studies should be 
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combined with other methods. Site-specific administration of exogenous receptor agonists and 
antagonists has historically been a commonly used complementary approach. As thoroughly 
detailed in Chapter 1, exogenous administration of melanocortin agonists in general increased, 
whereas antagonists decreased, locomotor activity levels in normal rats. This is in agreement 
with my conclusions from the characterization of ArcPomc-KO mice presented in Chapter 2.  
Puzzlingly, although there are a handful of reports based on administration of 
melanocortin agonists that agree with our conclusion that ArcPOMC plays an inhibitory role in 
the HPA axis, the majority of published studies conclude the opposite. The most likely reasons 
for this discrepancy are differences in the time scale of intervention, e.g. acute injection versus 
life-long knockout, as well as dosages of agonists used by different groups. In order to more fully 
understand the complex relationship between the neural melanocortin system and the HPA axis, 
further experiments must be performed. For example, it would be prudent to undertake a series 
of experiments in which varying doses of melanocortin ligands are administered for various 
lengths of time and HPA outcome measured.  
 The lack of Pomc expression in the Arc in our model has been well-validated by in situ 
hybridization (data not shown), immunohistochemistry (86), and semi-quantitative real-time 
PCR, but there is always the possibility that the primary genetic manipulation caused 
unidentified off-target effects. Additionally, compensation for the lack of ArcPomc may have 
occurred during development in the knockouts. To rule out these possibilities, the experiments 
conducted in Chapters 2 and 3 could be repeated in another genetic knockin mouse model with 
LoxP sites flanking the upstream neuronal Pomc enhancers (this mouse would first need to be 
generated). Site-specific injection of a Cre-expressing viral vector into the arcuate nucleus of 
adult mice would lead to excision of the neuronal enhancers and eliminate Pomc expression in 
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only those neurons. This method would circumvent possible off-target and developmental effects 
of the ArcPomc-KO allele and comparison of the phenotypes of the two genetic models would 
allow confirmation or revision of my conclusions.  
A useful mouse model that allows re-expression of ArcPomc upon injection of tamoxifen 
into adult ArcPomc-KO mice already exists (86). After rescue, approximately 70-80% of 
ArcPOMC neurons begin to express Pomc, but the degree of body weight normalization depends 
on the age and obesity of each mouse at the time of tamoxifen injection. Performing similar 
experiments as those described here in mice with restored ArcPomc expression at different ages 
could help to further unravel the relationship between ArcPOMC, obesity, locomotion, and the 
HPA axis. Normalization of these parameters by the restoration of ArcPomc expression in adult 
mice would strongly argue against the possibility of irreversible developmental consequences of 
Pomc deficiency.  
The specific roles of ArcPOMC identified in this report should be confirmed by rescue of 
the ArcPomc-KO.  This could be accomplished by treating ArcPomc-KO mice either acutely or 
chronically with melanocortin agonists or by activating downstream neurons using opto- or 
chemo-genetic approaches. Ideally, such an effort could also identify the key sites of 
downstream action. For example, if optogenetic activation of Mc4r-expressing cells in the PVH 
rescued the hyperactive HPA phenotype described in ArcPomc-KO mice, I could conclude that 
the Arc to PVH circuit is critical for POMC regulation of the HPA axis.  
However, efforts to identify possible downstream target sites of ArcPOMC in regulation 
of either the HPA axis or locomotor activity levels have thus far been unsuccessful. The neural 
circuitry controlling the HPA axis has been studied extensively but there is still a lot that is 
unknown. Diverse signals converge onto neurons in the paraventricular nucleus of the 
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hypothalamus (PVH) expressing CRH and/or AVP, which are activated by stress. Although 
mRNA levels of Avp in the hypothalamus and Avpr1b in the anterior pituitary were highly 
elevated in ArcPomc-KO mice, suggesting that ArcPOMC may normally inhibit AVP production 
and/or release, genetic deletion of Avpr1b did not rescue the observed HPA dysregulation. By 
process of elimination, these results suggest that it is CRH which mediates the HPA effects of 
melanocortin signaling. There are direct projections from POMC neurons to the PVH, and some 
CRH neurons in the PVH express Mc4r (170). However, Mc4R is Gs-coupled and 
pharmacologic administration of melanocortin agonists activates rather than inhibits these target 
cells. It is within the realm of possibility that melanocortins activate a noncanonical pathway 
specifically in CRH-expressing PVH neurons. Alternatively, POMC neurons could inhibit CRH 
neurons indirectly via an unidentified relay of GABAergic interneurons or some other anti-stress 
signal. The bed nucleus of the stria terminalis would be a logical candidate to study first because 
of its known afferent input from ArcPOMC neurons, integration of stress signals from other 
limbic nuclei, and efferent projections to the PVH (255). Testing this hypothesis via 
pharmacological or opto- or chemo-genetic approaches would be an extensive undertaking.  
 Neural mechanisms regulating the initiation and duration of spontaneous and voluntary 
locomotion are much less well-characterized than those regulating the HPA axis. In rodents, 
running wheel activity is rewarding and activates the dopaminergic system, so I hypothesized 
that decreased running wheel activity in ArcPomc-KO mice may be due to disrupted reward 
pathways. Classically, the melanocortin system is believed to be involved solely in 
homeostatically-regulated feeding, whereas other pathways were thought to regulate hedonic 
feeding, but recent evidence has showed extensive overlap of these two systems. In fact, 
impaired dopaminergic signaling has been characterized in other obese mouse models, including 
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ob/ob, which have decreased dopamine and TH levels (256). The reward deficiency hypothesis 
posits that decreased dopamine levels, reflecting an impaired reward system, may cause an 
animal to eat more in order to obtain the normal level of rewarding feeling (257). Conversely, 
others argue that excessive activation of reward pathways by increased dopamine could lead to 
overeating and obesity (258). A third possibility is that alterations in the dopaminergic pathway 
observed in obesity are secondary to and possibly compensatory for the hyperphagia and/or 
obesity. 
Using semi-quantitative real-time PCR and immunohistochemistry, however, we could 
find no differences between genotypes in the dopaminergic system. These were only a first-pass 
effort, were one-time static measurements of mRNA and protein levels in specific regions, and it 
certainly remains possible that the dopamine system could be dysregulated in ArcPomc-KO 
mice. In an attempt to determine a possible functional role of an altered reward system in the 
hyperphagia observed in ArcPomc-KO mice, I subjected them to a progressive ratio test wherein 
the effort required to obtain each progressive food pellet increased exponentially. ArcPomc-KO 
mice responded to this test with an equal breakpoint as WT for access to normal chow food 
(Figure 4.1), suggesting that the hyperphagia seen in this model is not due to enhanced rewarding 
value of food. Furthermore, it is clear that the dopaminergic reward pathways are grossly intact 
in ArcPomc-KO mice, as both WT and ArcPomc-KO mice developed conditioned place 
preference for morphine (Figure 4.2) and had identical locomotor sensitization to repeated 
morphine exposure.   
In contrast, the associative learning process that encodes reward, which has also been 
shown to involve dopamine, may be impaired in ArcPomc-KO mice, as they exhibited marked 
difficulty in initially learning to lever press for food in operant chambers (unpublished 
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observation). In this light, one could view the lack of increased running wheel activity with age 
(Figure 2.4) as an impairment in the association of running wheel activity with reward. 
Therefore, although we do not yet have direct evidence that ArcPomc-KO mice have 
dysregulated dopaminergic signaling, several signs point in that direction, and I feel that this line 
of research is worth pursuing. A next step would be to measure dopamine release in the nucleus 
accumbens under baseline conditions and after presentation of a reward, such as a sucrose pellet, 
to wildtype and ArcPomc-KO mice. 
Although it is unknown whether dopamine is involved, it has recently been discovered 
that activation of AGRP neurons encodes a negative valence whereas activation of PVH Mc4r-
expressing neurons in the hungry state encodes a positive valence (58,73). These findings lead 
me to postulate that activation of POMC neurons could encode a positive valence. To test this 
hypothesis, I could perform a conditioned place preference test wherein one side of the chamber 
is paired with optogenetic stimulation of ArcPOMC neurons. If place preference is observed, it 
would indicate that ArcPOMC neuron activation could encode a positive valence associated not 
only with eating but possibly with other stimuli and behaviors as well. To test that the valence 
signal is carried by POMC and not by other neuromodulators expressed in ArcPOMC neurons, 
these tests could be repeated in ArcPomc-KO mice or in wildtype mice pretreated with a 
melanocortin receptor antagonist. Furthermore, the response of ArcPomc-KO mice to more 
natural stimuli such as palatable food, sucrose water, or access to sex should be assessed, as it is 
becoming increasingly evident that all rewards may not activate reward pathways equally.  
 Another complementary angle to approach this question would be to measure the real-
time activation of ArcPOMC neurons in awake animals presented with various rewarding stimuli 
using recently developed in vivo calcium imaging techniques. Using these methods, ArcPOMC 
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neurons have recently been shown to become rapidly activated by exposure to food, but not by a 
non-food object, and the degree of activation was associated with the palatability of the food 
(57). Discovering the response of ArcPOMC neurons to other rewarding stimuli such as sucrose, 
drugs of abuse, or even access to a running wheel could help to unravel a possible role for these 
neurons in encoding valence of stimuli.  
 Although up until this point, I have discussed locomotor activity levels and HPA axis 
regulation as two separate phenomena, it is also possible that they are related. Acute and forced 
treadmill exercise is known to activate the HPA axis, but the HPA response to voluntary wheel 
running exercise seems to be more complex. Access to a running wheel for only two weeks in 
rats and four weeks in mice resulted in increased corticosterone levels, both basally and in 
response to a stressor and to ACTH injection, due to increased adrenal sensitivity to ACTH 
(198,199). However, after 6 additional weeks of voluntary wheel running, adrenal sensitivity and 
corticosterone levels were normalized. Another study showed that rats given access to running 
wheels for 6 weeks had a decreased HPA response to mild stressors but normal response to high-
intensity stressors (200). Interestingly, after 10 weeks of running wheel access, Zucker diabetic 
fatty rats had improved metabolic outcome associated with decreased corticosterone and adrenal 
sensitivity to ACTH (36).  
Similar long-term studies have not been reported in mice, but it is possible that the 
hyperactivity of the HPA axis that we observed in ArcPomc-KO mice could be secondary, at 
least in part, to sedentary behavior. On the other hand, corticosterone levels can also affect 
physical activity. Although this has most often been studied in the context of a novel 
environment or in response to administration of drugs of abuse (255), chronic corticosterone 
administration was also associated with decreased spontaneous home cage activity (259,260). 
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Therefore, it is possible that the decreased locomotor activity observed in ArcPomc-KO mice 
could be partly due to the hyperactive HPA axis. These are merely speculations and further 
studies would need to be performed to confirm a mechanistic relationship between locomotor 
activity and HPA axis activation in ArcPomc-KO mice.  
 Overall, I speculate that each physiologic role of hypothalamic POMC is performed in 
the service of defending body weight. Most obviously, melanocortin signaling decreases food 
intake. I have now shown by inference from the ArcPomc-KO mouse model that melanocortin 
signaling also tonically inhibits the HPA axis, preventing chronically increased corticosterone 
levels that can lead to increased feeding and fat deposition as well as decreased locomotor 
activity. Additionally, melanocortin signaling increases levels of voluntary locomotion. Whether 
these two pathways influence each other is at this point unclear, and much more work is needed 
to fully elucidate all the ways in which hypothalamic POMC affects physiology.   
  
115
Figure 4.1: Performance for food reward of ArcPomc-KO mice on a progressive ratio 
schedule of reinforcement. 4-6 month old mice were trained to lever press for access to a 
20-mg standard laboratory food pellet (TestDiet 5TUM) at a fixed ratio of 30. Mice were then 
fasted during the day and the progressive ratio started at onset of dark. The required number of 
presses, Y, for each pellet, x, increased according to the equation Y = 18e0.1x. Breakpoint was 
determined as the number of pellets acquired before a time-out period of 30 minutes passed 
with no pellet acquired. Each mouse was then administered enough food in the remaining dark 
period to maintain the mouse at 85% of starting body weight. The progressive ratio test was 
repeated for 10 nights in a row and the breakpoints on the last seven nights were averaged. 
Data were analyzed by two-way ANOVA using genotype and sex as the independent variables, 
but there were no differences between groups. N = 7-9 per sex and genotype.
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Figure 4.2: Conditioned place preference for morphine in ArcPomc-KO mice. This test 
was performed in 6-8 month old female mice. A two-chamber conditioned place preference 
box was constructed with each chamber measuring 40x20 cm and a 3x5 cm opening between 
the two sides. One chamber had a metal grid floor and white walls and the other chamber had 
an acrylic floor and black walls. On day 1, mice were placed on the metal-floored side and 
allowed to explore freely for 30 minutes. The preferred side, determined by measuring the time 
spent on each side by each mouse using Med Associates software, varied between mice but 
there was no consistent difference between groups. On days 2-9, mice were either injected i.p. 
with morphine (2 mg/kg) and placed on their least preferred side or with saline and placed on 
their preferred side, with the opening between chambers blocked. Treatments alternated so that 
each mouse underwent 4 days of each treatment. On day 10, the procedure for day 1 was 
repeated and the place preference ratio calculated (time on morphine side / total time). Data 
were analyzed by RMANOVA and there was a significant effect of treatment (F(1,11) = 39.0, 
P < 0.001) and an interaction (F(1,11) = 8.3, P < 0.05). N = 6-7 per genotype. * P < 0.05 by 
Sidak’s post hoc multiple comparisons test.
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